AUTHOR INDEX

VOLUME 33

Abdelal, A. T., 48
Abu Elteen, Khalid H., 726
Abu Hatab, Moeen A., 717, 726
Acar, J. F., 951
Ackerman, Bruce H., 142
Adams, Kenneth, 689, 1760
Adams, W. J., 356, 508
Adar, Rivka, 92
Ahearn, D. G., 48
Ahrens, J., 1242
Akahane, Kouichi, 1704
Alaghamandan, Hassan A., 1487
Alam, Khorshed, 1447
Albrecht, Janice K., 387, 396
Albrecht, Lisa M., 519, 1184
Albritton, William, 235, 1627
Aldridge, Kenneth E., 562
Al-Joburi, W., 2016
Allen, J. E., 526
Allen, N. E., 1121
Allen, Stanley D., 895
Allen, Stephen D., 562
Allen, William, 591
Al-Nakib, W., 522
Al-Obeid, S., 198
Amsterdam, Daniel, 2019
Anaissie, E., 1647
Anderson, Heather, 87
Anderson, M. D., 442
Anderson, Marge, 1160
Anderson, William L., 1549
Andremont, Antoine, 1400, 1540
Andries, K., 522
Antia, Noshir H., 866
Antinori, Andrea, 122
Anwar, Hosmin, 1824
Aoyama, Hiroshi, 785
Apitz-Castro, Rafael, 1641
Arai, Susumu, 331
Arakawa, Yoshichika, 63
Arcese, William, 1709
Archer, Gordon, 424, 460, 1335
Arditi, Moshe, 245
Argoudelis, Alexander D., 2089
Ariza, J., 987
Arnott, Wendy S., 1875
Asahara, Michinori, 1144
Asahi, Yoshinari, 1423
Assandri, Alessandro, 1791
Atichartakarn, Vichai, 1406
Auckenthaler, R., 1113, 2037
Auclair, Pierre, 1575
August, E. Michael, 2149
Aweeka, Francesca, 742
Awni, Walid M., 1927, 2012
Ayers, Kenneth M., 1428
Ayestaran, Isabel, 1622
Azimi, Parvin H., 1620

Baca, Oswald G., 621, 1052
Backhouse, C. I., 877
Baddour, Larry M., 801
Baiocchi, Pia, 580
Baker, Carol J., 1108
Baker, William R., 78
Baker-Zander, Sharon A., 1465
Balfour, Henry H., Jr., 1375
Balis, Frank M., 810
Ballard, Ronald C., 1393
Balzarini, Jan, 1291, 1864
Bandoh, Kaori, 242
Bannam, Trudi L., 1569
Barabás, György, 58
Barbaro, Daniel, 128
Bardos, Thomas J., 340
Barja, Juan L., 1674
Barlow, Margaret A., 53
Barnea, Ada, 788
Baron, S., 2126
Barrett, John F., 1697, 2027
Barrett, Leah J., 248
Barriere, Steven L., 519, 589, 1184
Barrow, G. I., 522
Barry, Arthur L., 562, 569, 944
Barry, D. W., 304
Barthélémy, Michel, 2160
Bartlett, John A., 1801
Bartlett, Karen H., 1368
Baume, Daniel, 1400
Bauriaud, R., 2152
Bawdon, Roger E., 1645
Bayer, A. S., 624
Beam, Thomas R., 850, 2019
Bean, Bonnie, 1375
Beauchamp, Denis, 1342, 1575, 2006
Becker, Susi, 369
Bedard, J., 1379, 1457
Bedows, Elliott, 400
Behr, Elke, 2109
Bellido, F., 937, 1113
Beneke, Everett S., 16
Benes, Solomon, 1721
Bennett, Peter M., 1116
Benson, John M., 1989
Bergdahl, Susanne, 1023
Berger, Stephen A., 593
Bergeron, Michel G., 1342, 1575, 2006
Bergeron, Yves, 1342
Berk, Steven L., 113
Berman, Jonathan D., 1860
Bernard, Evelyne, 871
Bernareggi, Alberto, 1791
Bernstein, David I., 1511
Berry, Susan J., 1101
Berryman, David I., 1346
Bertasso, A., 239, 1067
Bertino, Joseph S., Jr., 1890
Beskid, George, 1072
Bhatia, Gulshan, 1237
Bianco, Theresa M., 1890
Bille, Jacques, 1869
Birch, G., 1217, 1606
Bisno, Alan L., 597, 602
Bitar, N., 1686
Black, John R., 167
Blakley, Gerald A., 1908
Blaschke, Terrence F., 1237
Blok, P., 256
Blouin, Robert A., 291, 1952
Blum, M. Robert, 1801
Blum, Robert A., 1470
Bobadilla, Juan, 973
Bodey, G. P., 1647
Bolao, F., 987
Bolard, Jacques, 345
Bonmarchand, G., 391
Borchardt, Ronald T., 828, 1291
Borcherding, David R., 1291
Boscia, Jerome A., 1198
Bosso, J. A., 526
Bothwell, William M., 508
Bouvet, A., 198
Bowden, Bonnie J., 2034
Bowie, William R., 1774, 1778
Boyd, Malcolm R., 1765
Brajtburg, Janina, 345
Branch, Kieran R., 928
Branch, Robert A., 928, 1222
Brandimarte, C., 580, 1329
Brandt, Roger, 373
Brenner, Malcolm K., 503
Brian, E. Leigh, 1482
Bright, G. M., 277
Brismar, Bo, 204
Brocks, Valerie, 2101
Brown, Barbara A., 1631, 1845
Brown, Sharon Y., 820
Brumbach, Arlene, 771
Brummer, Elmer, 573
Brummett, Robert E., 791, 797
Brundage, Dianne M., 1375
Bryan, L. E., 624, 983, 1379, 1435, 1457
Bryant, Tanya D., 928
Bryson, Yvonne J., 649
Bubley, Glenn J., 862
Burdett, Vickers, 1373
Bure, Anne, 767, 1958
Burns, Gerard P., 977
Burns, Jane L., 136, 1247
Bush, Karen, 259, 264, 271, 1451
Bush, Larry M., 1198
Butler, Karina M., 1108
Butler, Thomas, 1447
Buu-Hoï, Annie, 529
Bycroft, Barrie W., 1516

Caggiano, Christine, 113
Calame, Wim, 980
Cameron, D. William, 612
Canton, Philippe, 871
Capobianco, John O., 156
Caraway, Nancy, 1111
Carbon, Claude, 767, 1506
Carlisle, Ricarda, 824
Caron, François, 767
Carpenter, Tim E., 670
Carratala, J., 987
Cartwright, Frank D., 103
Carver, Peggy L., 82
Cassidy, Lisa F., 2009
Cathcart, K. Sue, 356
Catherall, Elaine J., 693
Catto, Brian A., 1557
Cavenaghi, Luigi, 1791
Celesk, Roger A., 1921
Chaffin, D. O., 1878
Chai, T., 412
Chamberland, S., 624, 1457
Chambers, Henry F., 424, 991, 995, 1522, 1822
Chan, Chek C., 87
Chan, E. C. S., 2016
Chan, K., 1067, 1072
Chanal, Catherine M., 1915
Chang, Hernan R., 1748
Chapman, Beryl, 862
Chapman, J. S., 27, 239, 1067
Chapman, Sharon K., 862
Chastang, Claude, 1753
Cheek, William R., 1108
Cheesbrough, John, 1193
Chen, Yu-Ming, 452
Cheng, S.-L., 2016
Cheng, Yung-Chi, 340
Chiba, Kan, 1188
Chin, Nai-Xun, 1009, 1036, 1105, 1260, 1795
Chinnock, Barbara, 1375
Chirby, Daniel G., 2089
Chirgwin, Keith, 1634
Choma, Nadia, 820
Chopra, Ian, 1116
Chou, Ting-Chao, 53
Choudhury, Aniruddha, 866
Chouini-Lalanne, N., 1939
Chow, Anthony W., 1368
Christenson, James G., 2101
Chu, Chung K., 1729
Chu, Daniel T. W., 131
Cialdella, Joyce I., 2089
Claes, R., 1686
Claeys, Geert, 757
Clair, B., 933
Clarke, Barbara, 1588
Clavier, Françoise, 316
Cleary, Thomas G., 781
Cleeland, R., 1067, 1072
Closson, Sharon K., 508
Cluzel, Roger A., 1915
Coats, J. H., 2089
Cocchetto, David M., 801
Coen, Donald M., 1395
Cohen, Martin, 977
Cohen, Seth P., 1318
Cole, C. T., 1477
Cole, Stewart T., 2096
Coleman, Kenneth, 1580
Collatz, E., 951
Collette, N., 362
Collins, MarJeanne, 646
Collins, P., 635
Colonno, R. J., 1563
Connor, James D., 311
Conrad, Robert S., 1724
Contrepois, Alain, 345
Contreras, Ana Maria, 973
Cools, Marina, 1291
Coppenhaver, D. H., 2126
Corey, Lawrence, 649
Cornick, N. A., 835
Corpet, Denis E., 535
Corpet, Florence, 535
Cortés, Jorge, 973
Corvo, Donna L., 230
Costerton, J. William, 1824
Cottam, Howard B., 1487
Courvalin, Patrice, 10, 1373, 1958

Couvreur, Patrick, 1540
Cox, Susan, 2083
Cozens, R. M., 1819, 1864
Craig, William A., 35
Cramer, C. A., 2052
Crandall, Alan S., 396
Criddle, Richard S., 717, 726
Crumpacker, Clyde S., 862
Cullen, M. E., 886
Cummings, L. M., 1067
Cummings, Marinella, 1721
Cundy, Kenneth R., 164
Curby, William A., 2155
Cynamon, M. H., 1179
Cywes, S., 1358

Danner, Robert L., 1428
Darouiche, Rabih, 1326
Dasgupta, Mrinal, 1824
Datema, Roelf, 110
Davidson, Bruce A., 400
Davies, John M., 1193
Davies, Julian, 192
Davis, C. P., 442
Davis, Gail E., 1549
Davis, Robin L., 212
Davoulos, George, 1362
D'Costa, Lourdes J., 612
Decker, L. Christopher, 326
De Clercq, Erik, 185, 1291, 1482, 1864
Degré, Miklos, 680
Dekker, W., 256
de Lalla, Fausto, 1125
de la Maza, Lorena, 1383
de Lencastre, Herminia M., 1869
Delorme, F., 2016
DeMaria, Alfred, Jr., 1137
Deneer, Harry G., 235
DeOrio, Francis J., 498
Deppermann, Karl-Matthias, 1901
Derlot, Eliane, 10
Derouin, Francis, 1753
Desiderio, James V., 489, 906
Desrochers, Kelly L., 311
Deuel, Dianne M., 326
Devine, C., 198
de Wet, P. M., 1358
Dhillon, Jasvir, 1255
Diana, G. D., 2069
Dickinson, Gordon M., 597, 602
Dinya, Zoltán, 58
Diop, Djiby, 824
DiPiro, Joseph T., 817
Dix, B. A., 1067
Dixon, Dennis M., 1639
Dizon, Marycon, 1409
Dobrogosz, Walter J., 674
Domart, Yves, 345
Donabedian, Armen M., 233
Doran, Colette C., 156
Dorfman, Lynn C., 670
Dotevall, Leif, 1078
Dougherty, Thomas J., 498
Drach, John C., 1291, 1606
Draft, Kenneth, 1721
Drancourt, M., 2146
Drew, Richard H., 1801
Drugeon, Henri B., 1869
Drusano, George L., 618
Drwal, Laureen, 1841
Dubach, U. C., 957
Dubin, Donald T., 541
Dudley, Sharon M., 248
Duerden, Brian I., 970
Dufresne, Julien, 1201
Dunphy, Mary Gail, 1620
Durack, David T., 1735, 1811
Durcan, F. Jane, 396
Dutko, F. J., 2069
Dutschman, Ginger E., 340
Duval, Jean, 10
Dwyer, Patrick N., 1890

Eagon, Robert G., 1936
Ebden, P., 963
Ebert, Steven, 700
Ebisu, Takayuki, 1354
Ebringer, Libor, 1883
Edelstein, Martha A. C., 2132
Edelstein, Paul H., 2132
Edlind, Thomas D., 484, 2144
Edwards, David J., 1875
Edwards, Jeffrey R., 215
Edwards, Morven S., 1108
Edwards, Nadine, 1860
Efange, Simon M. N., 340
Eliopoulos, C. T., 1019
Eliopoulos, G. M., 470, 965, 1019, 1232
el Kouni, Mahmoud H., 824
Ellis, M. Nixon, 304, 1691
Eng, Robert H. K., 181
Englund, Janet A., 1375
Erardi, Francis X., 350
Eriksson, Bertil F. H., 115, 663, 1729, 2149
Eron, Lawrence, 649
Espinosa, Angeles, 973
Evans, Mark H., 700
Eveland, Michael R., 1275

Failla, Mark L., 350
Falkinham, Joseph O., III, 350
Fallat, Virve, 1072
Fantin, Bruno, 767
Fantoni, Massimo, 122
Farinotti, Robert, 1506
Farrell, Cathy A., 1697
Farrow, P. R., 963
Fasching, Claudine E., 566
Fass, Robert J., 1268
Fattal, Elias, 1540
Federico, Giovanni, 122
Fekete, Thomas, 164
Fernandes, Prabhavathi B., 78, 131, 1531
Fernandez, Cecilia, 1970
Fernandez-Larsson, Roberto, 1668
Ferraro, Mary Jane, 1232, 1383
Ferré, B., 951
Ferro, Santiago, 108
File, Thomas M., 924
Finegold, Sydney M., 369
Finkbeiner, Heidi C., 1280
Fisher, L. M., 886
Fisher, Melanie A., 1042, 1443
Fisher, Michael H., 340
Flamm, Robert, 1451
Flanagan, Cole, 1631, 1845
Fletcher, Courtney V., 1375
Flory, Marcella A., 1252
Flynn, G., 1217
Follis, Kathryn E., 1908
Fontana, Roberta, 120
Forgacs, Pierre, 2155
Forman, D. Michael, 1174
Forrest, Alan, 618
Foulds, George, 467, 714
Foulds, John, 412
Fox, Kaye E., 448, 791, 797
Franzblau, Scott G., 2004, 2115
Freiberg, Leslie A., 78
Frey, Felix J., 373, 1952
Frimerman, Hedva, 593
Froggatt, John W., 460
Frost, R. Wayne, 1118
Fuchs, Peter C., 562
Fujii, Tadashi, 785
Fujii, Yasuaki, 63
Fujimaki, Kazuo, 785
Fujimoto, Kouichi, 1167, 1804
Fujimoto, Teruo, 1388
Fujioka, Hisashi, 6
Fung-Tomc, Joan, 489, 498, 906
Furukawa, Hiroshi, 6

Galanakis, Nearchos, 1362
Galanos, Chris, 1724
Galetto, David W., 460
Galgiani, John N., 731, 1095
Gallegos, John, 212
Gallis, Harry A., 1801
Galvez, A., 437, 641
Gamba, Gerardo, 973
Gambertoglio, John, 742
Gangemi, J. David, 1864
Garaud, Jean Jacques, 871
Garcia, Isabel, 653
Garcia, Manuel, 369
Garcia Arenzana, José M., 1622
García García, M. I., 1650
García-Rodríguez, J. A., 1650
García Sánchez, E., 1650
García Sánchez, J. E., 1650
Gaudebout, Claude, 316
Geary, Ian, 970
Geers, Teresa A., 233
Gentile, G., 209, 580, 1329, 1709
Georgopapadakou, N. H., 27, 239, 322, 1067
Gerbaud, Guy, 1958
Gerding, Dale N., 566
Gerlach, E. Hugh, 562
Geshan, Andrea E., 1553
Gewain, K., 2052
Ghannoum, Mahmoud A., 717, 726
Giamarellou, Helen, 1362
Giardina, James A., 1553
Gibbs, Ronald S., 801
Gil, Francisco, 1641
Gilbert, David N., 1280
Gilbert, Teresa, 551
Gill, Charles J., 394
Gill, John H., 230
Gillikin, Sheila, 434
Gilljam, Gustav, 778, 2083
Gilmore, Michael S., 1588
Giménez-Gallego, G., 437
Ginsberg, David, 646
Ginsberg, R. S., 1179
Girard, Arthur, 1160
Girmenia, Corrado, 580
Giuliano, Marina, 1709
Gladue, R. P., 277
Glick, Alan, 1222
Godfrey, A. J., 1435
Goldman, Robert C., 156, 1058
Goldstein, David J., 1395
Goldstein, F. W., 951
Goldstein, Harvey R., 99
Gondal, Javed A., 1544
Gonzalez, Javier, 1970
Goodman, Larry J., 1385
Gootz, Thomas, 1160, 1697, 2027
Gorbach, S. L., 835
Gorea, Alfred, 593
Gorzynski, Eugene A., 591, 2019
Goswick, Claude B., 646
Goto, Sachiko, 1144
Gotuzzo, Eduardo, 1101
Gough, Lauren, 810
Gourde, Pierrette, 2006
Granich, George G., 311, 1275
Grasela, Thaddeus H., Jr., 615
Graybill, J. R., 1242
Grès, J. J., 391
Griffin, David R. J., 1580
Griffith, Brigitte P., 2149
Griffith, Dean L., 356
Griffith, Jeffrey K., 230, 1549
Griffiths, Steven G., 19
Grill, Susan P., 340
Grimwood, Keith, 41
Grindey, Amanda J., 215
Gristina, Anthony G., 813
Grout, Raymond J., 1516
Gu, Jian-Wei, 1998
Guay, David R. P., 1927, 2012
Guay, Gordon G., 2042
Gubbe, Sylvia L., 2034
Gudiol, F., 987
Guerrant, Richard L., 248
Gutman, Steven I., 591
Gutmann, L., 951
Guzman, Miguel, 1101
Guzzo, Joseph, 1553

Hackbarth, Corinne J., 991, 995
Haddad, John, 1443
Haemers, Achiel, 1
Hagberg, Lars, 1078
Hall, C. C., 322
Hall, E. C., 1855
Halstead, Diane C., 1553
Halstenson, Charles E., 2012
Hamanaka, Ernest, 1160
Hamill, Richard, 1326
Hammerschlag, Margaret R., 1634
Hancock, Robert E. W., 1207
Handsfield, H. Hunter, 167
Hannoun, P., 1286
Hansen, Lori M., 670
Hanslo, D., 1358
Hanson, Charles W., 1531
Hanson, Linda H., 573, 1391

Haraguchi, Yoshiko, 968
Harding, G. K. M., 1032
Hardy, Dwight J., 78, 1531
Hare, R. S., 2052
Harkonen, Scott, 1237
Harmenberg, Johan, 778, 2083
Harnden, Michael R., 1765
Harris, Steven C., 714
Harrison, Christopher J., 1511
Harrison, Nedra J., 1470
Hashem, R., 1647
Hashimoto, Masahisa, 1167
Hashizume, Terutaka, 1423
Hasobe, Masahide, 828
Hastings, Robert C., 657
Hawkins, Edith, 1111
Hayashi, Hideo, 805
Hayashi, Shoryo, 331
Hayashi, Toshio, 513
Healy, Daniel P., 474, 1841, 1994
Hedberg, Maria, 1302
Hedin, Linda A., 136, 1247
Heifets, Leonid, 1252, 1298
Heizmann, Peter, 373
Hejmanowski, Linda G., 99, 857
Helzner, Eileen C., 646
Henderson, Robert P., 710
Henritzy, L. L., 1878
Henry, M. J., 1228
Herter, Catherine, 2037
Hessen, M. T., 608
Heymans, C., 362
Higgins, P. G., 522
Hill, Catherine, 1400
Hill, E. L., 304
Hillen, Wolfgang, 1373
Hindes, R. G., 1019
Hinds, David, 1111
Hirano, Minoru, 489
Hiraoka, Masaki, 382, 398
Hirata, Cheryl A. I., 1927
Hird, David W., 670
Hirsch, Martin S., 53
Hirsh, Dwight C., 670
Hitchcock, Michael J. M., 844
Ho, D. H., 1647
Ho, Hsu-Tso, 844
Hobbs, J. N., Jr., 1121
Hobbs, Marcia M., 1735, 1811
Hochkeppel, Heinz-Kurt, 1864
Hoepelman, Ilja M., 684
Hof, Herbert, 404
Hoffbrand, A. Victor, 503
Höffken, Gert, 1901
Hoffman, Howard E., 924
Holazo, Alice A., 820
Hollis, Dannie G., 1845
Holst, Elisabet, 2142
Holtsclaw-Berk, Shirley, 113
Holý, Antonin, 185
Honore, Nadine, 2096
Hook, Edward W., III, 167
Hooper, David C., 283, 705, 1318, 1655, 1662
Hooton, Thomas M., 103, 1308
Hopfer, R. L., 152
Horaud, Théa, 529
Hoshino, Hiroo, 773
Hoshino, Kazuki, 1816
Hosley, John D., 508
Hospenthal, Duane R., 16
Hotta, Tomomitsu, 576
Hoyt, Jeanne, 103
Hsia, Karen, 920
Hsieh, Mark, 1237
Hsiung, G. D., 1563, 1600
Hu, J. M., 1600
Hua, Mei, 171
Huang, Liang, 2149
Huang, Shu-Hui, 171
Hubbert, Ted, 1090
Hughes, Stephen H., 115
Huyer, Gregory, 297
Huyer, Marianne, 297

Ibrahim, Ashraf S., 717
Inderlied, Clark B., 176
Inoue, Eiko, 2157
Inoue, Matsuhisa, 382, 785, 1837, 1980
Inoue, Takami, 576
Inoue, Yoshimasa, 785
Iravani, Abdollah, 1212
Isaacson, R. E., 277
Ishizaki, Takashi, 1188
Islam, M. R., 1447
Israelski, Dennis M., 30
Ito, Hideo, 63
Itoh, Takahiko, 576
Itoh-Yamashita, Naoko, 1535
Iwata, Kazuo, 2118

Jaakkola, Jouni, 1741
Jabes, Daniela, 1869
Jackson, Edwin K., 1222
Jacobson, Mark A., 736, 742
Jacobus, N. V., 1964
Jacoby, George, 583, 1131
Janssen, P. A. J., 522, 2063
Jarlier, Vincent, 2096
Jarvest, Richard L., 1765
Jefferson, Sara, 1569
Jefford, Charles W., 1748
Jennings, Roger A., 813
Jenssen, Warren D., 541
Jewesson, Peter J., 1778
Jimenez, Rafael, 1970
Jimenez-Sanchez, Gerardo, 973
Johnson, Caroline C., 369
Johnson, Carolyn, 1308
Johnson, Nelson, 1428
Johnson, Victoria A., 53
Johnston, J. Linda, 460
Joiner, Keith A., 1428
Jolley, Weldon B., 1487
Jones, Brian M., 970
Jones, Cheryl Slater, 1592
Jones, Ronald N., 562, 569, 944
Jorgensen, James H., 560
Judson, Franklyn N., 649
Jullien, Soizic, 345
Jungbluth, Gail L., 839, 850
Jusko, William J., 839, 850

Kaatz, Glenn W., 519, 589, 1184
Kadam, Sunil K., 1058
Kager, Lars, 204
Kain, K. C., 1609
Kalz, Carola, 1901
Kaminsky, Ronald, 881
Kanawati, Lama, 474
Kanda, Toshihisa, 1354
Kanemasa, Yasuhiro, 805
Kaojarern, Sming, 1406
Kapell, Kathi S., 118
Kaplan, Raymond L., 1385
Karle, Isabella L., 1081
Karle, Jean M., 1081
Kashimoto, Shigeki, 1167
Katahira, Junichi, 513
Kato, Junko, 1188
Kato, Nobuo, 63
Katoh, Naoki, 242
Kawa, Diane E., 1000
Kawa, Zenzaburo, 1188
Kawaguchi, Hiroshi, 489
Kaye, Donald, 1198
Keane, William F., 2012
Kearns, Gregory L., 142
Keith, Barry R., 479
Keith, D. D., 1067, 1072
Keller, Erich, 1952
Kelly, H. William, 212
Kelly, M. T., 1609
Kelly, Niamh M., 1207
Kennedy, J., 1032
Kennedy, Stephen, 1522
Kenny, George E., 103
Kenny, Michael T., 2012
Kernutt, Ian, 693
Kesado, Tadataka, 1302
Kessler, Harold A., 118
Kessler, Robert E., 489, 498, 906
Ketelaar-van Gaalen, Petra A. G., 1153
Khan, M. Yousuf, 1409
Khatri, Ashok, 1090
Kibbler, Christopher C., 503
Kido, Nobuo, 63
Kiel, Frank W., 1409
Kilburn, James O., 1493
King, Michael, 1860
Kinkel, Arlyn W., 615
Kinsolving, C. Richard, 895
Kirst, Herbert A., 1413, 1419
Kissinger, Jessica, 1588
Kitaoka, Setsuko, 1291
Kitayama, Rieko, 513
Kiuchi, Akira, 1144
Kneer, J., 291, 957, 1952
Knight, Paul R., 400
Ko, Howard, 356, 508
Kobayashi, Shinzo, 331
Koburov, George T., 71
Koch, William C., 248
Koeppe, Peter, 1901
Kohlhepp, Sue J., 1280
Kohli, Romesh K., 1470
Kohnen, Paul W., 1280
Kohno, Yoshiro, 751
Kojima, Tsuyoshi, 254, 1167, 1804, 1980
Kolonoski, Peter T., 176
Komatsu, Takayuki, 63
König, Herbert, 2109
Konno, Masatoshi, 1535, 1624
Konno, Tasuke, 1291
Kono, Megumi, 1354
Korfmann, Gisela, 1946
Koshida, Rie, 778, 2083
Kotera, Yasuo, 1896
Kotsifaki, Helen, 124
Koumans, Emily, 1668
Kouno, Kaoru, 1167
Kovarik, John M., 684
Krahenbuhl, James L., 657
Krajčovič, Juraj, 1883
Krawczyk, Steven H., 1606
Krogstad, Donald J., 311, 1275
Kubista, Louise N., 1000
Kuck, N. A., 1964
Kumada, Nobuo, 6
Kumada, Teppei, 513
Kumano, Katsuhiko, 513
Kunz, Samuel, 418
Kuo, Ming-S., 2089
Kurobe, Nobuyuki, 1167
Kuroda, R., 886
Kurth, Reinhard, 2109

Labia, Roger, 1131, 1915, 2160
Labidi, Abdelhakim, 1845
Lafredo, Stephen C., 164
Laisne, M. J., 933
Lake-Bakaar, Desmond M., 110
Lam, Kan, 1824
Lander, Roger D., 710
Lapierre, Stephen, 1403
LaRocco, Mark, 781
Latham, Robert H., 1308
Laurent, John P., 1108
Lavelle, George C., 2034
Le Bouguénec, Chantal, 529
Le Bras, Jacques, 316
Lebsack, M. E., 615
Leclercq, Pascale, 871
Leclercq, Roland, 10
Lee, B. Craig, 983
Lee, Bonita, 336
Lee, James W., 1932
Lee, Luen F., 820
Lee, Margaret E., 970
Lee, P. Gregory, 1042
Lefevre, J. C., 2152
Legakis, Nicholas J., 124
Leggett, James E., 35
Legrand, C., 1647
Lemos, Manuel L., 1674
Lent, K., 1878
Leon-Barua, Raul, 1101
Leport, Catherine, 871
Lerebours, G., 391
Leroy, J., 391
Letendre, Elaine D., 776
Lettieri, John T., 1118
Levesque, Roger C., 1201
Levin, Myron J., 649
Levison, M. E., 608
Levy, H. B., 2126
Levy, Stuart B., 1318, 1373
Lew, Daniel P., 2037
Lewandowski, Gail A., 340
Leysen, Dirk C., 1
Lien, Dena M., 136, 1247
Ligtvoet, E. E. J., 256
Lin, C., 1932
Lin, Tai-Shun, 2149
Lindborg, Björn, 110
Lindholm-Levy, Pamela, 1252, 1298
Lindmark, Ann, 2137
Lindqvist, Lennart, 1302
Lipschitz, Ellen R., 1072

Lobe, D. C., 304, 1691
Lockey, Peter M., 1516
Lockhart, Pete, 551
Lode, Hartmut, 1901
Loebenberg, David, 1932
Lohr, Jacob A., 248
Long, Jeffry M., 167
Lopez, A. Pascual, 362
López, Guadalupe, 973
Lopez-Berestein, G., 152
Low, Donald E., 108, 585
Löwer, Johannes, 2109
Luby, James P., 128
Lucain, Christine, 937
Lucher, Lynne A., 452
Lucia, H. L., 1563
Luginbuehl, Brigitte, 1952
Lukehart, Sheila A., 1465
Luman, J. Ileice, 1631
Lumeau, Solange, 535
Luo, Weixing, 336
Lutun, Philippe, 871
Lynch, Patricia, 1975
Lynch, William H., 19

MacDonald, Kelly S., 612
MacKenzie, J. M., 2092
Mackowiak, Philip A., 128, 1645
Mader, Jon T., 689, 1760
Maderazo, Eufronio, 82
Maehlen, Thore, 680
Magner, Alan, 646
Maguiña, Ciro, 1101
Maher, Louise A., 560
Makris, Antonios, 124
Malet-Martino, M. C., 1939
Malmborg, Anna-Stina, 204
Mandragos, Kostantine, 1362
Manning, Janice T., 142
Maoleekoonpairoj, Savitree, 1406
Maqueda, M., 437, 641
Marang, Brice, 1400
Marchand, Sylvie, 1342
Mariño, Eduardo, 1970
Mariño, Leonardo, 1641
Markiewicz, Z., 1819
Marquez, Victor E., 1291
Marshall, Vincent P., 2089
Martinez, M., 641
Martino, P., 209, 580, 1329, 1709
Martino, R., 1939
Marzella, L., 1526
Mason, Edward, 1108, 1111
Massari, P., 391
Massip, Patrice, 871
Masuda, Kazuo, 1144
Masuyoshi, Shinji, 489
Matsen, J. M., 526
Matsuda, Kouji, 1423
Matsuhashi, Michio, 424, 1624
Matsushita, Osamu, 805
Matthews, Julie A., 877
Mattie, Herman, 147, 980
Mattioni, Doriane, 2160
Matzke, Gary R., 2012
Mayoux, J. J., 391
McCabe, William R., 1137
McCapes, Richard H., 670
McCormack, William M., 1721
McCully, Cynthia, 810
McDaniel, Donna, 1531
McDonald, Edith J., 78
McDougall, Linda, 1869
McDowell, Thomas D., 1680
McGarry, David H., 1072
McGeer, Allison, 585
McGowan, John E., Jr., 1855
McGuirk, Paul R., 1697
McHugh, Gail L., 283, 705
McIntyre, Kyle A., 731, 1095
McKee, James G., 828
McKinlay, M. A., 2069
McManus, Albert T., 1936
McMurry, Laura M., 1318, 1373
Medearis, Donald N., Jr., 1975
Medoff, Gerald, 345
Megran, David W., 1774
Mehta, R. T., 152
Mendelman, P. M., 1878
Merigan, Thomas C., 1237
Merle-Melet, Myriam, 1506
Merlin, Toby L., 230, 1549
Mertens, J. C. C., 256
Mertz, Gregory, 801
Meulemans, A., 1286
Meunier, F., 362
Michel, G., 1939
Micozzi, A., 209, 1329
Midez, J. A., 152
Mierzwa, R., 2052
Mikami, Yuzuru, 2140
Milhous, Wilbur K., 1090
Millar, A. J. W., 1358
Miller, G. H., 2052
Mills, John, 736, 742
Minami, Akira, 1167, 1804
Miörner, Håkan, 2142
Mistry, Nerges F., 866
Mita, K., 1636
Mitchell, Jeffrey T., 895
Mitchison, D. A., 1255
Mitsuhashi, Susumu, 382, 398, 785, 1837, 1896, 1980, 2157
Miyamoto, E., 1636
Miyashiro, Deborah, 1451
Mizen, Linda, 693
Moellering, Robert C., Jr., 470, 965, 1019, 1232
Monson, Thomas P., 142
Montay, A., 391
Monto, Arnold S., 387
Moody, Julia A., 566
Mooney, Martha L., 474
Moon-McDermott, Lotus, 541
Moore, Carol Wood, 1592
Morales, Ana, 1970
Morand, Annick, 1915
Mori, Masashi, 63
Morrison, Louis, 1760
Mortensen, Joel E., 771
Motawy, Mohamed S., 717, 726
Movin, Gunilla, 1023
Moyzis, Robert K., 1549
Muhvich, K. H., 1526
Mulder, Ross, 1588
Mullany, Peter, 1569
Mullen, George B., 895
Muñoz Baroja, Isabel, 1622
Muñoz Bellido, J. L., 1650
Murata, Y., 1636
Muratani, Tetsuro, 513
Murray, B. E., 1019
Murray, D. M., 412
Murray, Martha, 649
Murray, Patrick R., 1588
Musher, Daniel, 1326
Muto, Yoshinori, 242
Myers, R. A. M., 1526
Mylotte, Joseph M., 1500
Myrvik, Quentin N., 813

Nadler, Harriette L., 2155
Nagai, Yoshiyuki, 576
Nagarajan, R., 1477
Nahata, Milap C., 1989
Naik, Sandesh, 1614
Nairn, Kevin, 215
Nakagawa, Susumu, 1423
Nakamura, Mika, 254, 1167
Nakamura, Shinichi, 254, 1167, 1804
Nakata, Katsuhisa, 1167
Nares, Felipe, 973
Nash, Donald R., 1845
Naylor, Paul T., 813
Ndinya-Achola, Jackoniah O., 612
Neill, P., 963
Nelson, Jeffrey A., 1385
Nelson, P. E., 1647
Nervo, Properzio, 122
Neu, Harold C., 1009, 1036, 1105, 1260, 1795, 1998
Neveaux, John L., 2034
Newborg, M. F., 277
Ng, Eva Y., 283
Ngeleka, Musangu, 1575
Nguyen, Vu X., 434
Nicas, T. I., 1121, 1477
Nichols, Brian P., 2042
Nicolas, Marie-Helene, 2096
Nicolle, L. E., 1032
Nightingale, Charles H., 82, 1118
Nikaido, Hiroshi, 1201, 1831
Nishiyama, Yukihiro, 6
Nix, David E., 99, 434, 1006
Noble, Robert C., 801
Nonoguchi, Ritsuko, 1624
Noone, Paul, 503
Nord, Carl Erik, 204, 1302, 2137
Norman, Allyn, 1006
North, Ginnie Lee T., 915
North, Thomas W., 915
Novak, Ervin, 508
Novelli, Andrea, 1009, 1036
Nozawa, Ryushi, 1388
Nuttall, Charles E., Jr., 646

Öberg, Bo, 778
Oberhelman, Richard A., 1101
Ochi, Kohichi, 1188
O'Connell, Kevin, 1668
O'Day, Dennis M., 1222
O'Donnell, James J., 736
Ofek, Itzhak, 92
Ogenstad, Stephan, 1023
Ogura, Michinori, 576
O'Hara, Koji, 1354
O'Hara, Patrick J., 551
Ohmiya, Keiichi, 1354
Ohnishi, Akihiro, 928, 1222
Ohnishi, Tomok, 1222
Ohta, Michio, 63
Ohtake, Norikazu, 1423
Ohue, Tomio, 1167
Okabe, Akinobu, 805
Okamoto, Ryoichi, 382
Oki, Toshikazu, 489
Oliva, Brunello, 1116
Oliver, N. M., 635
Olson, Christy A., 2075
Oppenheim, Beryl A., 87
Ordy, Mark J., 895
Orgel, Ira, 248
Ortisi, Giuseppe, 1125
Osada, Yasuaki, 1704, 1816
O'Shea, Patricia, 824
O'Sullivan, John F., 2004
Otto, M. J., 2069
Ou, Ching, 1326

Padula, Ana, 1822
Pagano, Joseph S., 1482
Page, John W. J., 1580
Page, William J., 297
Pallares, R., 987
Pallavicini, Federico, 122
Palmer, G. S., 1179
Palmer, Gene C., 895
Pangon, Beatrice, 767, 1958
Pantosti, Annalisa, 1709
Paradis, Timothy J., 53
Park, M. K., 1526
Parks, L. W., 2092
Parpia, Salvinaz H., 99
Parrillo, Joseph E., 1428
Parrott, Patricia L., 1855
Pascual, Alvaro, 653
Pasko, Mary T., 850, 1500
Pasternack, Mark S., 1975
Patterson, Jan Evans, 251
Patterson, Jean L., 1668, 2009
Patterson, William H., 1428
Pattyn, Stefaan R., 1
Paul, Gerard C., 1958
Pauloin, Danielle, 1237
Paycha, F., 1286
Pechère, J. C., 937, 1113, 1748, 2037
Pedersen, Niels C., 915
Péduzzi, Jean, 2160
Peña, José Carlos, 973
Pennell, Daniel R., 1000
Penrose, Audrey, 1516
Penyige, András, 58
Perdikaris, George, 1362
Perea, Evelio J., 653
Pérez Trallero, Emilio, 1622
Perfect, John R., 1735, 1811
Perkins, Robert M., 223
Perronne, Christian, 871
Persson, Ingela, 2137
Peters, Gary R., 356, 508
Petersen, P. J., 1964
Peterson, Lance R., 566
Peterson, Phillip K., 1927
Petit, Agnès, 1915
Pfaller, Michael A., 562
Philippon, Alain, 1131, 1958, 2096
Phillips, Katherine L., 551
Piercy, Elizabeth A., 128, 1645
Pinto-Schuster, E., 951

Pioget, J. C., 933
Pitsakis, P. G., 608, 1198
Pizzo, Philip A., 467, 810, 1932
Plaisance, Karen I., 618
Plorde, James J., 551
Plummer, Francis A., 612
Poast, J., 2126
Pocino, Marisol, 92
Polak, Annemarie, 1639
Polk, Ron E., 474, 1841
Polónyi, Jozef, 1883
Ponticas, Suzanne, 394
Poon, Ruby, 585
Poplack, David G., 810
Porat, Reuven, 1137
Potel, Gilles, 767
Potter, Andrew, 235
Prentice, H. Grant, 503
Preston, D. A., 1121, 1477
Prior, Richard B., 1268
Privitera, Gaetano, 1125
Prusoff, William H., 2149
Prymas, L. A., 762
Pussard, Eric, 316
Pyszczynski, Dennis R., 710

Quenzer, Ronald W., 212
Quinn, John P., 1451
Quintiliani, Richard, 82, 1118

Rabbani, G. H., 1447
Rabin, Harvey R., 41
Racht, Edward, 1841, 1994
Radov, Lesley A., 895
Rahman, Aquilur, 1544
Ramachandran, C., 1217
Ramasesh, Nalini, 657
Rao, G. M., 442
Raoult, D., 621, 2146
Rathod, Pradipsinh K., 1090
Ravdin, Jonathan I., 960
Rawling, Eileen G., 1207
Ray, Barbara S., 167
Redding, Judith S., 560
Redditt, Shawn D., 1631
Reed, Kelyenne E., 1680
Regamey, Patrick, 937
Regnier, B., 933
Remington, Jack S., 30
Remmel, Rory P., 171
Renneberg, J., 1714
Restrepo, B. I., 1242
Retsema, James, 1160
Reuben, A., 1647
Rice, L. B., 470, 1019
Richard, George A., 1212
Rigan, David, 857
Rinaldi, Enrico, 1125
Rinaldi, Michael G., 714
Ripley, Daniel, 920
Rizk, N., 951
Rizzardini, Giuliano, 1125
Rizzo, M., 2052
Roberts, Marilyn C., 103, 1373, 1611
Roberts, Pacita L., 1308
Robertson, Alex F., 817
Robillard, Norman J., 1921
Robins, Morris J., 336
Robins, Roland K., 1487
Robinson, Richard D., 1222
Roblin, Patricia M., 1634
Rock, David T., 474
Rode, H., 1358
Rofman, Barry A., 646
Rogers, Alvin L., 16
Rogge, M. C., 2069
Rognerud, Cheryl, 1326
Rohner, Peter, 2037
Rollof, Jan, 2142
Roman, Miriam J., 1052
Romanowski, Barbara, 2049
Ronald, A. R., 612, 1032
Rood, Julian I., 1346, 1569
Rosenberg, Fred, 2155
Rosenberg, Ivan, 185
Rosin, Eberhard, 700
Rosner, J. L., 412
Rotstein, Coleman, 2019
Rubin, Marc, 1428, 1932
Rubin, Robert H., 1975
Ruck, Robert, 1614
Rufi, G., 987
Ruiz, Rosa, 1101
Running, Joyce A., 1813
Ruoff, Kathryn L., 1383
Rybak, Michael J., 519, 1184

Saarimäki, Mariaana, 1023
Sabath, L. D., 407
Sabra, Ramzi, 928, 1222
Sack, R. Bradley, 1101
Sage, Roger J., 503
Saha, Gita, 1260, 1795
Sahai, Jan, 1841, 1994
Sahm, Daniel, 71, 1451, 1588
Saikawa, Isamu, 513
Saito, Hajime, 429
Saitoh, Hidehiko, 576
Sakaguchi, Takashi, 331
Sakaguchi, Yuzo, 1167
Salstrom, Sara-Jane, 924
Sanada, Minoru, 1423
San-Blas, Felipe, 1641
San-Blas, Gioconda, 1641
Sanchez-Pescador, Ray, 1813
Sande, Merle A., 418
Sanders, Christine C., 1313, 1946
Saneyoshi, Mineo, 576
Santiago, Yaffita, 973
Santini, C., 209, 580, 1329
Santoro, Domenico, 1125
Sarubbi, Felix A., 113
Sarzotti, M., 2126
Satake, Sachiko, 398
Sato, K., 785, 1816
Saunders, Carol A., 1137
Sawant, A. D., 48
Scarffe, J. Howard, 87
Schabel, A. A., 1477
Schaefer, Felicity, 2101
Scheer, Robert R., 649
Schell, Ronald F., 1000
Schentag, Jerome J., 99, 434, 615, 857, 1006, 1470
Schinazi, Raymond, 115, 663, 1729, 2149
Schnipper, Lowell E., 862
Schoenfeld, David, 1975
Schollaardt, T., 624, 1457
Schorling, John B., 248
Schultz, Robert W., 615
Schultz-Darken, Nancy J., 700
Schwartz, Stanley A., 387
Sedlock, David M., 326
Sedman, Allen J., 615
Segreti, John, 118, 1385
Seki, Jun-Ichi, 773
Sekiguchi, Masayasu, 1704
Selleseth, D. W., 304
Sentochnik, Deborah E., 1232
Seo, Susan M., 519, 589, 1184
Serfass, Debra A., 164
Serra, P., 209, 580, 1329
Seta, Nathalie, 1506
Setlow, Jane K., 1627
Sfikakis, Paul, 1362
Shafran, Stephen D., 1368
Shahar, Abraham, 788
Shahrier, M., 1447
Shalit, Itamar, 593, 788
Sharma, Brahma S., 1487
Sharon, Nathan, 92
Shaw, K. J., 2052
Shawar, Ribhi, 781
Shayegani, A., 762
Shen, Shueh-Hui, 1443
Sherertz, Robert J., 1174
Sherwood, Charles, 311
Shields, David S., 248
Shih, David J., 705
Shimada, Nobuyoshi, 773
Shimizu, Kihachiro, 513
Shimizu, Masanao, 1167
Shipman, C., Jr., 1217
Shlaes, D. M., 192, 198
Shlaes, J. H., 192, 198
Shryock, Thomas R., 771
Shuhua, Xiao, 1557
Shungu, Daniel L., 394
Sides, Gregory D., 1413, 1419
Sifuentes, José, 973
Signs, Steven A., 924
Silva, M., 835
Simich-Jacobson, Valerie, 498
Simmons, Roy D., 895
Simor, Andrew E., 108
Singh, I. P., 2126
Singlas, E., 933
Sirot, Danielle L., 1915
Sirot, Jacques L., 1915
Sjövall, Jan, 1023
Skilogiannis, Joanna, 960
Skinner, Michael H., 1237
Slaney, Leslie, 1627
Slattery, John T., 1046
Sligh, James E., 345
Smee, Donald F., 1487
Smith, A. L., 1046, 1878
Smith, Barry L., 1721
Smith, David S., 646
Smith, Marilyn S., 1482
Smith, Sharon M., 181
Smith, Stephen R., 1193
Snipes, Kurt P., 670
Sokolowski, Sharon, 1160, 1697
Solliday, Joanne, 1588
Solomon, Donald D., 1174
Sommadossi, Jean-Pierre, 824
Song, Min Dong, 1624
Southgate, W. Michael, 817
Souza, Kathleen S., 283
Sox, Thomas E., 2075
Spearing, Ruth, 1193
Spector, Stephen A., 920
Spector, Thomas, 1691
Spohr, Marlene, 1617
Sriyuktasuth, P., 2126
St. Georgiev, Vassil, 895
Stamm, Walter E., 1308
Standefer, Jim, 212
Standiford, Harold C., 618
Stathakis, Charalambos, 1952
Stein, Daniel J., 1927
Stein, Theodore A., 977
Steinberg, Brenda, 212
Steingrube, Vincent A., 1845
Stempien, Michelle M., 1813
Sterling, Lisa P., 1994
Stevenhead, William, 1222
Stevens, David A., 573, 1391
Stevens, Robert C., 82
St.-Germain, Guy, 1403
Stiver, H. Grant, 1368
Stoeckel, K., 291, 957, 1952
Strand, James C., 895
Stuck, Andreas E., 373
Stull, T. L., 1878
Suga, Tetsuya, 751
Sutcliffe, Joyce A., 2027
Suter, S., 1113
Sutton, David, 1765
Sutton, Lorraine, 583
Suwa, Toshio, 751
Suzuki, Satoru, 336
Swanson, Robert N., 1531
Swartz, Morton N., 283, 705
Swartz, Rodney P., 1544
Sweeney, Kevin, 82, 1118
Swenson, C. E., 1179
Swindell, R., 87
Szabó, Gábor, 58
Szabó, István, 58

Takahashi, Katsutoshi, 773
Takayama, Kuni, 1493
Takeuchi, Tomio, 773
Takita, Tomihisa, 773
Talarico, Todd L., 674
Talbot, Hazel, 2049
Talbot, M. Kelly, 2101
Tam, Y. K., 957, 1952
Tan, James S., 924
Tanaka, Nobuo, 1423
Tancrède, Cyrille, 1400
Tardif, Dominique, 1575
Tardif, Manon, 1342
Tarry, William F., 1042, 1443
Täuber, Martin G., 418
Taylor, Diane E., 1373
Taylor, N., 522
Tecson-Tumang, Flor, 181
Tenover, Fred C., 551
Tessier, Diane, 1403
Testa, R. T., 1964
Then, R. L., 1113
Thomas, Donald J., 615
Thomas, William D., Jr., 1335
Thompson, M., 1032
Thornsberry, Clyde, 569, 944
Thorson, Stephen M., 248
Tillotson, Lucia E., 541
Tisdale, James E., 1500
Tiwari, Kiran, 2160
To, Marina, 41
Tolman, R. L., 1563
Tom, Corrynne, 30
Tomasz, Alexander, 1869
Tomatsu, Kozo, 489
Tomioka, Haruaki, 429

Tomoda, Yutaka, 576
Tonin, Enrico A., 120
Toothaker, Roger D., 1046
Toranzo, Alicia E., 1674
Torseth, John, 1237
Townsend, Leroy B., 1606
Townsend, Raymond J., 618
Trang, John M., 142
Traub, Walter H., 1617
Treadwell, Thomas L., 1137
Treharne, John D., 1393
Trenholme, Gordon M., 118, 1385
Trias, Joaquim, 1201
Trzaskos, J. M., 1228
Tsai, Che-Chung, 1908
Tsai, Yuan H., 906
Tschink, Gabriele, 1901
Tsuchiya, Masamitsu, 1188
Tsuji, Akiyoshi, 1144
Tsushita, Keitarou, 576
Tucker, Richard M., 573
Tunér, Kajsa, 1302
Tuomanen, E., 1819
Turgeon, Pierre L., 776
Turner, Philip J., 215
Turner, Ronald B., 396
Tyrrell, D. A. J., 522
Tyrrell, David L. J., 336
Tzouvelekis, Leonidas S., 124

Ubukata, Kimiko, 1535, 1624
Ueda, M., 1636
Uehara, Hiroko, 2118
Ueno, Kazue, 242
Underwood, Fred L., 142
Une, Tsutomu, 1704, 1816
Uno, Jun, 2140
Unowsky, Joel, 1072
Uphoff, Timothy S., 700
Upshon, Pauline A., 1580
Urdea, Mickey S., 1813
Urias, B., 1032
Ushijima, Ryosuke, 1423

Vaara, Martti, 1741
Vachon, F., 933
Valadez, Alba, 973
Valdivia, E., 437, 641
Vallois, Jean-Marie, 767
van Biesen, Tim, 1824
Van Cutsem, Jan, 2063
van de Klundert, Jos A. M., 1153
Vanden Bussche, G, 522
van der Auwera, P., 362, 1686, 1783
Van der Meer, J., 635
van der Waals, Ron, 980
van Furth, Ralph, 147, 980
Van Gerven, Frans, 2063
van 't Wout, J. W., 147, 635
Venditti, M., 209, 580, 1329, 1709
Venezia, R. A., 762
Verdier, Françoise, 316
Verdon, Michael S., 167
Vere Hodge, R. Anthony, 223, 1765
Verghese, Abraham, 113
Verhoef, Jan, 684
Verschraegen, Gerda, 757
Viladrich, P. F., 987
Vilde, Jean-Louis, 871
Vince, Robert, 171
Vladoïanu, I. R., 1113
Vliegenthart, John S., 1153
Vrang, Lotta, 778
Vulpillat, M., 1286
Vuye, Armand, 757

Wacker, P., 1113
Wahren, Britta, 778, 2083
Waite, Nancy M., 1875
Walawander, Cynthia, 857
Walder, M., 1714
Waldvogel, Francis A., 2037
Walker, Bruce D., 53
Walker, James B., 452
Walker-Caprioglio, H. M., 2092
Wall, Laurel A., 1592
Wallace, Jack E., 714
Wallace, Richard J., Jr., 1631, 1845
Walmer, Kathy A. R., 1801
Walsh, Thomas J., 467, 1932
Wannop, Christine, 215
Warbasse, Lawrence H., 1875
Warr, Glenn, 906
Warren, M. M., 442
Watanabe, Kunitomo, 242
Watanabe, Masato, 1837
Watanabe, Mitsuru, 968
Watanabe, Yasuo, 513
Waters, R., 304
Watkins, J. D., 322
Weaver, Robert E., 1845
Webb, Lawrence X., 813
Weber, Michele, 10
Weidekamm, Erhard, 373
Weinberg, S., 442
Weiner, N., 1217
Weiss, W. J., 1964
Welage, Lynda S., 857
Weller, Sandra K., 1395
Weller, Stephen, 1801
Wendeler, Michael, 1198
Wetherby, Shauna, 167
Wexler, Hannah M., 369
White, Catherine A., 1046
White, Geoff, 479
White, Kenneth E., 2004
Wiley, E. A., 1878
Wilkie, Julie M., 1569
Willetts, Valerie, 1774, 1778
Willey, S. H., 1019
Williams, Bruce A., 400
Williams, James S., 857
Williams, M. Denise, 248
Williams, N., 1217
Williams, Paul, 1516
Williamson, R., 192, 198
Wills, Robert J., 820
Willson, Philip J., 235, 1627
Wilson, H. Robert, 479
Wilson, Rebecca W., 1631
Wilton, John H., 99, 615, 857
Withnell, Erica S., 215
Wolff, M., 933
Wolfson, John S., 283, 705, 1318, 1655, 1662
Wong, Edward S., 1308
Wong, Justina, 1368
Wong, S., 624, 1457
Wood, Craig A., 1280
Woodnutt, Gary, 693
Woods, Donald E., 41
Woods, M. G., 2069
Worobec, Elizabeth A., 297
Wren, Brendan W., 1569
Wright, Kathleen A., 1735, 1811
Wu, C. Y. E., 1121
Wu, Martin, 176
Wyke, A. W., 886

Yamamoto, Tomoko, 746
Yamashita, Takako, 2118
Yang, Z. H., 1563
Yao, Joseph D. C., 965
Yarnall, Michele, 1908
Yasuda, Takashi, 513
Yazawa, Katsukiyo, 2140
Yeaman, Michael R., 621, 1052
Yearsley, Peter J., 1393
Yeni, Patrick, 345
Yeom, Yoon-Hee, 171
Yi, Augusto, 1101
Yocum, D. M., 762
Yogev, Ram, 245
Yokota, Takeshi, 1388
Yoshida, Hideo, 751
Yoshida, Hiroaki, 254, 1167
Yoshida, Shonen, 576
Young, Lowell S., 176
Youssef, Mohammad, 1540
Yuk, Jae H., 1118

Zafriri, Dina, 92
Zak, Oto, 418
Zerilli, Luigi F., 1791
Zervos, Marcus J., 251
Zheng, Duo-Kai, 2149
Zimmerman, Cheryl L., 171
Zweygarth, Erich, 881
Zwickl, Beth E., 167

SUBJECT INDEX
VOLUME 33

A1110U
  combinations
    acyclovir, 1691
      herpes simplex virus type 1, 1691
  herpes simplex virus
    type 1, 1691
A-56620
  Enterococcus spp., 71
aacC2
  nucleotide sequence, 1153
AAC(3)-I
  DNA probe, 551
  resistance gene, 551
AAC(6')-II
  P. aeruginosa, 2052
6'-*N*-Acetyltransferase
  P. aeruginosa, 2052
Acinetobacter calcoaceticus
  AT-4140, 1980
  BO-1341, 1423
Acinetobacter spp.
  amikacin, 1617
  amoxicillin, 1617
  amoxicillin-clavulanic acid, 1617
  ampicillin, 1617
  ampicillin-sulbactam, 1617
  AT-4140, 1167
  aziocillin, 1617
  aztreonam, 1617
  BMY 40062, 906
  cefixime, 1617
  cefotaxime, 1617
  ceftazidime, 1617
  ciprofloxacin, 1617
  clavulanic acid, 1617
  doxycycline, 1617
  gentamicin, 1617
  imipenem, 1617
  mezlocillin, 1617
  netilmicin, 1617
  norfloxacin, 1617
  ofloxacin, 1617
  piperacillin, 1617
  polymyxin B, 1617
  Ro 23-9424, 1072
  SM-7338, 562
  sulbactam, 1617
  tetracycline, 1617
  ticarcillin, 1617
  ticarcillin-clavulanic acid, 1617
  tobramycin, 1617
  trimethoprim-sulfamethoxazole, 1617
Acquired immunodeficiency syndrome
  cytomegalovirus retinitis
    foscarnet, 742
  feline immunodeficiency virus model, 915
Acridone alkaloids
  malaria, rodent, 6
  P. yoelii, 6
  Plasmodium spp., 6
Actinobacillus actinomycetemcomitans
  spiramycin, 2016
Actinomyces pleuropneumoniae
  R plasmid
    streptomycin-sulfonamide, 235
Actinomyces spp.
  N,N'-dialkylpolymethylenediamines, 1636
Acyclovir
  combinations
    A1110U, 1691
    herpes simplex virus type 1, 1691
  comparative activity
    BRL 39123, 223
    9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, 223
    interferon, alpha, 649
  herpes genitalis, 649
  herpes simplex virus, 649
    ribonucleotide reductase mutants, 1395
    type 1, 223, 1691
    type 2 resistance, 635
  herpesvirus
    high-dose continuous infusion, 1375
  mouth lesions
    chemotherapy induced, 862
    herpes simplex virus, 862
    radiation induced, 862
Adenosine
  combinations
    ara-sangivamycin, 1606
    cytomegalovirus replication, 1606
    DNA synthesis, 1606
S-Adenosylhomocysteine
  9-(*trans*-2',*trans*-3'-dihydroxycyclopent-4'-enyl)-adenine, 828
  9-(*trans*-2',*trans*-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine, 828
  murine cell growth inhibition, 828
  vaccinia virus, 828
Aerobes
  benznidazole, 404
  nifurtimox, 404
Aerococcus viridans
  chloramphenicol resistance, 529
  erythromycin resistance, 529
  minocycline resistance, 529
  R plasmid, 529
  resistance
    genetic basis, 529
  streptomycin resistance, 529
  tetracycline resistance, 529
Aeromonas salmonicida
  exoprotease, 19
  outer membrane proteins, 19
  resistance, low level, 19
Ajoene
  P. brasiliensis, 1641
Alcaligenes faecalis
  ciprofloxacin
    DNA synthesis, 1457
    uptake, 1457
Alcaligenes spp.
  AT-4140, 1167
ALP 201
  anaerobes, 2137
  comparative activity
    cefoxitin, chloramphenicol, clindamycin, imipenem, metronidazole, and piperacillin, 2137
Alteromonas strain P-31
  antibacterial substance
    purification and characterization, 1674
Aluminum-magnesium antacid
  amoxicillin bioavailability, 1901
  amoxicillin-clavulanic acid bioavailability, 1901
  cefixime pharmacokinetics, 1994
  cephalexin bioavailability, 1901
  doxycycline bioavailability, 1901
AM-1091
  B. catarrhalis, 1036
  Bacteroides spp., 1036
  Citrobacter spp., 1036
  comparative activity
    ceftazidime, ciprofloxacin, gentamicin, imipenem, and ofloxacin, 1036
  E. coli, 1036
  E. faecalis, 1036
  Enterobacter spp., 1036
  Enterobacteriaceae, 1036
  H. influenzae, 1036
  Klebsiella spp., 1036
  Neisseria spp., 1036
  Pseudomonas spp., 1036
  S. pneumoniae, 1036
  Staphylococcus spp., 1036
  X. maltophilia, 1036
Amdinocillin
  N. meningitidis, 1622
Amifloxacin
  comparative activity
    aztreonam, ciprofloxacin, imipenem, lomefloxacin, norfloxacin, oxacillin, and vancomycin, 762
  E. coli
    DNA gyrase, 1837
  Enterobacteriaceae, 762
    outer membrane mutants, 1837
    resistance, spontaneous, 1837
  Enterococcus spp., 71
  mycoplasmas, 103
  S. typhimurium, 1837
  Staphylococcus spp., 762
Amifloxacin metabolites
  comparative activity
    aztreonam, ciprofloxacin, imipenem, lomefloxacin, norfloxacin, oxacillin, and vancomycin, 762
  Enterobacteriaceae, 762
  Staphylococcus spp., 762
Amikacin
  Acinetobacter spp., 1617
  B. avium, 771
  B. bronchiseptica, 771
  comparative activity
    aztreonam, 1137
    capreomycin, kanamycin, and streptomycin, 1298
    ciprofloxacin and imipenem, 176
  E. coli
    postantibiotic effect, 1714
  gram-negative infections, 1137
  liposomal
    M. avium complex, 1179
  M. avium, 1298
  M. avium complex, 176, 1179
  M. tuberculosis, 1298
  nephrotoxicity predictors, 973
  P. aeruginosa
    postantibiotic effect, 1714
  pharmacokinetics, 973
    aplastic anemia, 1406
    hematologic malignancies, 1406
  S. aureus
    postantibiotic effect, 1714
  Streptococcus spp., 580
4-Amino-5-bromo-7-(2-hydroxyethoxymethyl)pyrrolo(2,3,-*d*)pyrimidine
  comparative activity

acyclovir, 1600
guinea pig lymphotropic herpesvirus, 1600
Aminocyclitol synthesis
L-glutamine:keto-*scyllo*-inositol aminotransferase, 452
3-*N*-Aminoglycoside acetyltransferase
deoxyribonucleotide sequence, 551
DNA probe, 551
resistance gene, 551
Aminoglycoside-modifying enzymes
dactimicin, 1998
P. aeruginosa, 2052
Staphylococcus spp., 1335
Aminoglycosides
comparative activity
aztreonam, 1137
E. coli
tetracycline resistance gene, 230
uptake and *tet* expression, 1549
G. lamblia, 484
gram-negative infections, 1137
minireview, 797
ototoxicity, 797
P. aeruginosa, 1368
pharmacokinetics, 448
S. typhimurium
uptake and *tet* expression, 1549
sodium hydroxide extraction, 448
trichloroacetic acid extraction, 448
6-Aminopenicillanic acid
C. freundii β-lactamase induction, 1116
P. aeruginosa
β-lactamase induction, 1435
cell surface changes, 1435
Amopyroquin
malaria, 316
P. falciparum, 316
pharmacokinetics, 316
Amorolfine
W. dermatitidis, 1639
Amoxicillin
Acinetobacter spp., 1617
C. pylori, 1650
combinations
aluminum magnesium hydroxide, 1901
bioavailability, 1901
gonococcal infections, 801
gonorrhea, 167
N. gonorrhoeae, 167
pirenzepine, 1901
probenecid, 167, 801
ranitidine, 1901
N-formyl peptide conjugate
E. coli, 1516
immunostimulatory properties, 1516
S. aureus, 1516
pharmacokinetics, 1901
Amoxicillin-clavulanic acid
Acinetobacter spp., 1617
combinations
aluminum magnesium hydroxide, 1901
bioavailability, 1901
pirenzepine, 1901
ranitidine, 1901
E. coli resistance, 595
letter to the editor, 595
pharmacokinetics, 1901
Amoxicillin-probenecid
comparative activity
cefuroxime axetil, 801
ofloxacin, 167
gonococcal infections, 801
gonorrhea, 167
N. gonorrhoeae, 167
Amphotericin B
Aspergillus spp., 2063
C. albicans, 147, 1804
Candida spp., 1443
candidiasis, 1544
combinations
C. albicans, 152, 1804
cancer patients, 362
deoxycholate, 362
gramicidin S, 152
human erythrocytes, 152
interleukin-1α, 1804
comparative activity
fluconazole, 1443
fluconazole and itraconazole, 147
liposomal amphotericin B, 1544
Fusarium spp., 1647
high-pressure liquid chromatography, 362, 1989
liposomal
antibody, attached, 16
C. albicans, 16, 152, 345
C. neoformans, 345
human erythrocytes, 152, 345
unilamellar vesicles, 345
nephrotoxicity
sodium status, 1222
pediatric infections, 1989
pharmacokinetics
children, 1989
S. cerevisiae
ergosterol specificity, 2092
tissue concentrations and bioactivity, 362
W. dermatitidis, 1639
Ampicillin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
bactericidal activity determinants, 1046
C. pylori, 108
combinations
E. faecalis, 1019
endocarditis, 1019
pharmacokinetics, 1470
sulbactam, 1019, 1470
comparative activity
ampicillin-sulbactam, daptomycin, imipenem, and vancomycin, 1019
E. coli, 382, 1046
E. faecalis, 1019
endocarditis, 1019
N-formyl peptide conjugates
E. coli, 1516
immunostimulatory properties, 1516
S. aureus, 1516
meningitis, pneumococcal
dose, 418
dosing interval, 418
duration of treatment, 418
polyisohexylcyanoacrylate nanoparticle bound
salmonellosis, 1540
S. muenchen resistance, 1113
S. pneumoniae, 418
salmonellosis, 1540
Streptococcus spp., 580
Ampicillin-sulbactam
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
comparative activity
ampicillin, daptomycin, imipenem, and vancomycin, 1019
E. faecalis, 251, 1019
endocarditis, 1019
H. influenzae type b, 1620
pharmacokinetics
renal insufficiency, 1470
Anaerobes
ALP 201, 2137
benznidazole, 404
nifurtimox, 404
Antacids
cefixime pharmacokinetics, 1994
doxycycline
pharmacokinetics, 434
enoxacin pharmacokinetics, 615
Antibiotic AS-48
amino acid composition, 437
E. faecalis subsp. *liquefaciens*, 641
purification, 437
Antibody
combinations
cytomegalovirus, 1975
ganciclovir, 1975
cytomegalovirus, 1975
Antifungal agents
combinations
antineoplastic agents, 717, 726
C. albicans, 717
cancer patients, 717, 726
Candida spp., 726
T. cutaneum, 726
efficacy-safety profiles, 895
isoxazolidine derivatives, 3,5-substituted, 895
Antimalarial agents
enpiroline
crystal and molecular structure, 1081
Antineoplastic agents
combinations
antifungal agents, 717, 726
C. albicans, 717
cancer patients, 717, 726
Candida spp., 726
T. cutaneum, 726
Aphidicolin
herpes simplex virus
ribonucleotide reductase mutants, 1395
Aplastic anemia
amikacin pharmacokinetics, 1406
Apramycin
G. lamblia, 484
Arabinogalactan
M. smegmatis
ethambutol, 1493
Ara-sangivamycin
combinations
adenosine, 1606
cytomegalovirus replication, 1606
DNA synthesis, 1606
phosphorylation in infected and uninfected cells, 1606
Arboviruses
antiserum, 2126
poly(ICLC), 2126
poly(ICLC)-antiserum, 2126
Area under the killing curve
description, 1500
Artemether
S. mansoni

in vitro, in vivo, and histopathologic effects, 1557
AS-48
amino acid composition, 437
E. faecalis subsp. *liquefaciens*, 641
purification, 437
Aspergillosis
saperconazole
normal and immunocompromised animals, 2063
Aspergillus fumigatus
imidazole analogs, 895
triazole analog, 895
Aspergillus spp.
amphotericin B, 2063
cilofungin, 1391
flucytosine
metabolism, 1939
saperconazole, 2063
AT-4140
A. calcoaceticus, 1980
Acinetobacter spp., 1167
Alcaligenes spp., 1167
B. fragilis, 1167, 1980
Branhamella spp., 1167
Brucella spp., 1167
C. perfringens, 1167
Campylobacter spp., 1167
Chlamydia spp., 1167
comparative activity
ciprofloxacin, enoxacin, norfloxacin, and ofloxacin, 1167
ciprofloxacin, methicillin, norfloxacin, and ofloxacin, 1980
E. coli, 1167, 1980
DNA gyrase, 1980
Enterobacteriaceae, 1167
Enterococcus spp., 1167
Flavobacterium spp., 1167
gram-negative organisms, 1167
gram-positive organisms, 1167
Haemophilus spp., 1167
K. pneumoniae, 1980
Legionella spp., 1167, 1980
Moraxella spp., 1167
Mycobacterium spp., 1167
Mycoplasma spp., 1167
Neisseria spp., 1167
P. aeruginosa, 1980
Pseudomonas spp., 1167
S. aureus, 1980
S. marcescens, 1980
Staphylococcus spp., 1167
Streptococcus spp., 1167
Xanthomonas spp., 1167
Atalaphillinine
malaria, rodent, 6
P. yoelii, 6
Plasmodium spp., 6
Athletes, obese
cefotiam pharmacokinetics, 1188
Athymic mouse model
herpes simplex virus type 1, 304
ATP
bismuth subsalicylate, 2075
Autolysins
CGP 31608, 1819
imipenem, 1819
3′-Azido-2′,3′-dideoxythymidine
bone marrow toxicity, 576
human immunodeficiency virus, 576
3′-Azido-2′,3′-dideoxyuridine-5′-triphosphate
human immunodeficiency virus type 1 reverse transcriptase, 1729
simian immunodeficiency virus reverse transcriptase, 1729
3′-Azido-3′-deoxythymidine
combinations
cytomegalovirus, 663
2′,3′-dideoxycytidine, 920
foscarnet, 663, 778
human immunodeficiency virus, 778, 926
human immunodeficiency virus type 1, 663, 1482
phosphonoformate, 663
9-(2-phosphonylmethoxyethyl)adenine, 1482
PMEA, 1482
comparative activity
ampicillin and trimethoprim, 479
E. coli, 479
feline immunodeficiency virus, 915
human immunodeficiency virus, 920
type 1, 1482
S. dublin, 479
Azidothymidine
combinations
pyrimethamine, 30
T. gondii, 30
pharmacokinetics, 810
Azidothymidine triphosphate
DNA polymerase gamma, 2109
human immunodeficiency virus type 1 reverse transcriptase, 2109
Azithromycin
C. pneumoniae, 1634
E. histolytica, 960
uptake, 277
Azlocillin
Acinetobacter spp., 1617
combinations
ceftazidime, 503
netilmicin, 503
neutropenia, 503
pharmacokinetics, 710
AZT
combinations
human immunodeficiency virus type 1, 1482
9-(2-phosphonylmethoxyethyl)adenine, 1482
PMEA, 1482
pyrimethamine, 30
T. gondii, 30
human immunodeficiency virus type 1, 1482
Aztreonam
Acinetobacter spp., 1617
β-lactamases, 951
comparative activity
amikacin and tobramycin, 1137
E. coli, 382
gram-negative infections, 1137
K. pneumoniae
resistance, 1451
N. meningitidis, 1622
P. aeruginosa, 526

Bacillus spp.
Ro 23-9424, 944
Bacillus subtilis
mupirocin transport, 156
BACTEC 460
M. leprae, 2115
Bacteremia
gram-negative organisms, 1855
nosocomial infections, 1855
Bacterial vaginosis
clotrimazole, 970
fenticonazole, 970
metronidazole, 970
miconazole, 970
tetracycline, 970
Bacteroides fragilis
AT-4140, 1167, 1980
BMY 40062, 906
BO-1341, 1423
erythromycin accumulation, 242
josamycin accumulation, 242
macrolide accumulation, 242
S-ofloxacin, 1105
QA-241, 1144
rokitamycin accumulation, 242
Bacteroides fragilis group
cefotetan, 394
cefoxitin, 394
ceftizoxime, 394
chloramphenicol, 394
clindamycin, 394
imipenem, 394
metronidazole, 394
piperacillin-tazobactam, 1964
susceptibility testing, 394
Bacteroides spp.
AM-1091, 1036
FK482, 1795
SM-7338, 215, 1009
spiramycin, 2016
Banzi virus
antiserum, 2126
poly(ICLC), 2126
poly(ICLC)-antiserum, 2126
7-thia-8-oxoguanosine, 1487
Benznidazole
antibacterial activities, 404
Benzoyl peroxide
lipids
P. acnes, 326
P. acnes, 326
β-Lactamases
aztreonam resistance, 951
B. catarrhalis, 1845
biological fluids, 776
BRL 42715, 1580
BRO, 1845
C. butyricum, 1302
C. freundii
6-aminopenicillanic acid induction, 1116
cefpirome, 398
CAZ-5, 2160
cefaclor, 1313
cefixime, 1313
ceftazidime, 2160
cefuroxime, 1313
cephalexin, 1313
cephalosporins, 1958
resistance, 951
characterization, 259
classification, 264, 271
CP-65,207 hydrolysis, 1160
E. cloacae
AmpC, *ampG* essential for, 1946

E. coli, 382, 757, 1958
peptidoglycan synthesis, 2101
E. faecalis, 251, 1019
extended spectrum
minireview, 1131
FK482, 1795
H. influenzae, 1878
H. influenzae type b
ampicillin-sulbactam, 1620
K. oxytoca, 63
K. pneumoniae, 757, 951, 1451, 2096
multiple, isolated at same hospital, 1915
M. lacunata, 1845
M. nonliquefaciens, 1845
ME1228, 1260
minireviews, 259, 264, 271, 1131
Moraxella subgenus *Moraxella*, 1845
mRNA
lincomycin, 805
P. aeruginosa, 776
6-aminopenicillanic acid induction, 1435
cefepime, 498
SM7338, 1232
S. aureus, 331
SHV-3, 2096
SHV-5, 951
SM-7338, 1009
synthesis
lincomycin, 805
TEM, 1915
TEM-4, 1958
TEM-10, 1451
β-Lactams
combinations
neutropenia, 503
E. coli
peptidoglycan synthesis, 2101
P. aeruginosa, 1368
Biliary tract infections
cefamandole, 977
Bioassays
flucytosine, 1403
Biofilm
antibiotic interaction, 1824
in vitro chemostat system, 1824
Biomaterials
Staphylococcus spp., coagulase negative
antibiotic resistance, 813
Bismuth subsalicylate
binding and killing of bacteria, 2075
pH, 2075
E. coli, 2075
ATP, 2075
Blastomyces dermatitidis
cilofungin, 1391
ICI 195,739, 573
Blastomycosis
ICI 195,739, 573
Bleomycin
chromatin cleavage and degradation
growth phase dependency, 1592
S. cerevisiae, 1592
BMY 28232
comparative activity
BMY-28488, cefixime, cefotiam, and cefuroxime, 489
E. cloacae, 489
E. coli, 489
P. vulgaris, 489
pharmacokinetics, 489
prodrug esters, 489
S. aureus, 489
BMY 40062
Acinetobacter spp., 906
B. fragilis, 906
C. difficile, 906
C. trachomatis, 906
comparative activity
ciprofloxacin and ofloxacin, 906
Enterobacteriaceae, 906
Enterococcus spp., 906
P. aeruginosa, 906
pharmacokinetics, 906
S. aureus, 906
Staphylococcus spp., 906
Streptococcus spp., 906
U. urealyticum, 906
BO-1341
A. calcoaceticus, 1423
B. catarrhalis, 1423
B. fragilis, 1423
comparative activity
cefoperazone, cefotaxime, and ceftazidime, 1423
Enterobacteriaceae, 1423
H. influenzae, 1423
Pseudomonas spp., 1423
S. aureus, 1423
Streptococcus spp., 1423
Bone marrow recipients
norfloxacin
oral and intestinal floras, 1709
pefloxacin
oral and intestinal floras, 1709
Bordetella avium
amikacin, 771
ampicillin, 771
ampicillin-sulbactam, 771
cefoperazone, 771
cefotaxime, 771
ceftazidime, 771
ceftriaxone, 771
cefuroxime, 771
cephalothin, 771
chloramphenicol, 771
erythromycin, 771
gentamicin, 771
mezlocillin, 771
penicillin, 771
piperacillin, 771
rifampin, 771
tetracycline, 771
ticarcillin, 771
tobramycin, 771
trimethoprim-sulfamethoxazole, 771
Bordetella bronchiseptica
amikacin, 771
ampicillin, 771
ampicillin-sulbactam, 771
cefoperazone, 771
cefotaxime, 771
ceftazidime, 771
ceftriaxone, 771
cefuroxime, 771
cephalothin, 771
chloramphenicol, 771
erythromycin, 771
gentamicin, 771
mezlocillin, 771
penicillin, 771
piperacillin, 771
rifampin, 771
tetracycline, 771
ticarcillin, 771
tobramycin, 771
trimethoprim-sulfamethoxazole, 771
Bordetella parapertussis
ampicillin, 968
cefaclor, 968
cefatrizine, 968
cefoperazone, 968
cefotaxime, 968
cephalexin, 968
cephalothin, 968
chloramphenicol, 968
erythromycin, 968
josamycin, 968
minocycline, 968
moxalactam, 968
nalidixic acid, 968
penicillin, 968
piperacillin, 968
streptomycin, 968
sulfamethoxazole, 968
tetracycline, 968
Bordetella pertussis
QA-241, 1144
Branhamella catarrhalis
AM-1091, 1036
β-lactamases, 1845
BO-1341, 1423
cefpodoxime proxetil, 113
erythromycin
resistance, 1631
plasmids, 1845
Ro 23-9424, 944, 1072
tetracycline
resistance, 1631
Branhamella spp.
AT-4140, 1167
SM-7338, 215, 1009
BRL 39123
comparative activity
acyclovir, 223
herpes simplex virus type 1, 223
metabolism, 223
mode of action, 223
oral prodrug, 1765
pharmacokinetics, 1765
BRL 42715
β-lactamases, 1580
Citrobacter spp., 1580
combinations
amoxicillin, 1580
comparative activity
amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavulanic acid, cefotaxime, and clavulanic acid, 1580
Enterobacter spp., 1580
Enterobacteriaceae, 1580
BRL 42810
BRL 39123 oral prodrug, 1765
pharmacokinetics, 1765
Brucella melitensis
ciprofloxacin, 1409
difloxacin, 1409
ofloxacin, 1409
rifampin, 1409
streptomycin, 1409
tetracycline, 1409
trimethoprim-sulfamethoxazole, 1409
Brucella spp.
AT-4140, 1167
Burn wounds
mupirocin, 1358
S. aureus, 1358

Cadmium
M. scrofulaceum, accumulation and transport by, 350
Caffeine
ciprofloxacin pharmacokinetics, 474
disposition
ciprofloxacin, effect of, 474
Campylobacter coli
porins, 297
Campylobacter jejuni
ceftibuten, 781
enteritis
early treatment, 248
erythromycin, 248
porins, 297
trimethoprim-sulfamethoxazole, 248
Campylobacter pylori
amoxicillin, 1650
ampicillin, 108
cefetamet, 1650
cefixime, 1650
ceftetrame, 1650
cefuroxime, 1650
cinoxacin, 108
ciprofloxacin, 108
dirithromycin, 1650
enoxacin, 108
erythromycin, 108, 1650
fleroxacin, 108
fluoroquinolones, 108
gastritis, 256
lomefloxacin, 108
nalidixic acid, 108
nitrofurantoin, 108
nonulcerative dyspepsia, 256
norfloxacin, 108, 256
pefloxacin, 108
roxithromycin, 1650
tetracycline, 108
tigemonam, 1650
trimethoprim-sulfamethoxazole, 108
Campylobacter spp.
AT-4140, 1167
lomefloxacin, 1385
temafloxacin, 1385
Cancer patients
antifungal-antineoplastic agents, 726
interactions, 717
C. albicans, 717
Candida spp., 726
P. aeruginosa
risk of colonization with antibiotic treatment, 1400
T. cutaneum, 726
Candida albicans
amphotericin B, 147, 152, 1804
liposomal, 152
potassium leakage, 152
amphotericin B, liposomal, 345
antibody, attached, 16
amphotericin B-gramicidin S, 152
liposomal, 152
potassium leakage, 152
antibody attached to liposomal amphotericin B, 16
antifungal-antineoplastic interactions, 717
cancer patients, 717
cilofungin, 1822
endocarditis, 1735, 1822
endophthalmitis, 1735
fluconazole, 147, 1042
gramicidin S, 152
liposomal, 152
potassium leakage, 152
gramicidin S-amphotericin B, 152
liposomal, 152
potassium leakage, 152
imidazole analogs, 895
interleukin-1α, 1804
interleukin-1α–amphotericin B, 1804
interleukin-1α–miconazole, 1804
itraconazole, 147
liposomal amphotericin B, 345
antibody, attached, 16
P. anomala toxin, 48
SCH39304, 1095, 1735
triazole analog, 895
Candida spp.
amphotericin B, 1443
antifungal-antineoplastic effects, 726
cancer patients, 726
cilofungin, 1391
fluconazole, 1443
imidazole analogs, 895
piritetrate, 2118
triazole analog, 895
Candidiasis
amphotericin B, 1544
liposomal, 1544
cilofungin, 1811
fluconazole, 1042
SCH39304, 1735
Capreomycin
comparative activity
amikacin, kanamycin, and streptomycin, 1298
M. avium, 1298
M. tuberculosis, 1298
Carbovir
bioavailability, 171
high-pressure liquid chromatography, 171
pharmacokinetics, 171
Castanospermine
combinations
human immunodeficiency virus type 1, 53
human immunodeficiency virus type 2, 53
zidovudine, 53
cat
C. perfringens, 1569
C. difficile, 1569
Catheter-related infections
dicloxacillin catheter coating
S. aureus, 1174
intraluminal colonization, 2023
letter to the editor, 2023
S. aureus
dicloxacillin catheter coating, 1174
teicoplanin, 1193
vancomycin, 1193
CAZ-5
peptide sequencing, 2160
Cefaclor
B. parapertussis, 968
β-lactamase, 1313
comparative activity
cefuroxime axetil, 1212
Enterobacteriaceae, 1313
P. multocida, 2142
urinary tract infections, 1212
Cefadroxil
P. multocida, 2142
Cefamandole
biliary excretion, 977
pancreatic excretion, 977
Streptococcus spp., 580
Cefatrizine
B. parapertussis, 968
Cefazolin
combinations
clavulanic acid, 331
gentamicin, 1553
P. aeruginosa, 1553
peritoneal dialysis fluid bactericidal activity, 1553
S. aureus, 331
Staphylococcus spp., 1553
sulbactam, 331
comparative activity
clindamycin, 1760
osteomyelitis, 1760
pharmacokinetics
surgical wounds, 700
S. aureus, 1760
Cefcanel
P. multocida, 2142
Cefepime
β-lactamases, 498
cephalosporin-resistant gram-negative bacteria, 498
Citrobacter spp., 498
E. coli, 382
Enterobacter spp., 498
Enterobacteriaceae, 498
high-performance liquid chromatography, 1326
P. aeruginosa, 498
soft tissue penetration in paralysis, 1326
Cefetamet
C. pylori, 1650
pharmacokinetics
age, 291
renal insufficiency, 1952
Cefetamet pivoxil
pharmacokinetics
age, 291
ascending doses, 957
renal insufficiency, 1952
Cefixime
Acinetobacter spp., 1617
β-lactamase, 1313
C. pylori, 1650
Enterobacteriaceae, 1313
H. influenzae, 1878
high-performance liquid chromatography, 1994
pharmacokinetics
antacid, aluminum-magnesium, 1994
Cefmetazole
biliary excretion, 1970
choleretic effect, 1970
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
comparative activity
penicillin, 1465
high-performance liquid chromatography, 356
N. gonorrhoeae, 164
pharmacokinetics, 356, 508
predicted theoretical tissue versus actual skin window fluid levels, 924
probenecid pretreatment, 356
skin window technique, 924

syphilis, 1465
Cefonicid
pharmacokinetics
age, 142
renal function, 142
Cefoperazone
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
colon surgery prophylaxis, 835
E. coli, 35, 382
high-pressure liquid chromatography, 857
intestinal flora, 835
K. pneumoniae, 35
N-methylthiotetrazole disposition, 857
P. aeruginosa, 35
protein binding, 566
S. aureus, 35
serum ultrafiltrate, 35
Cefotaxime
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
E. coli, 382
K. pneumoniae
resistance, 2096
N. meningitidis, 1622
Streptococcus spp., 580
Cefotetan
B. fragilis group, 394
high-pressure liquid chromatography, 857
N-methylthiotetrazole disposition, 857
Cefotiam
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
pharmacokinetics
obese athletes, 1188
Cefoxitin
B. fragilis group, 394
E. coli, 382
high-performance liquid chromatography, 356
N. gonorrhoeae, 164
pharmacokinetics, 356
Cefpirome
C. freundii
cephalosporinase, 398
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
E. coli, 382
Cefpodoxime
H. influenzae, 1878
Cefpodoxime proxetil
B. catarrhalis, 113
Ceftazidime
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
β-lactamases, 2160
combinations
azlocillin, 503
interleukin-1α, 1804
neutropenia, 503
P. aeruginosa, 1804
piperacillin, 503
comparative activity
pefloxacin, 1362
ticarcillin and ticarcillin-clavulanic acid, 693
E. coli, 382
resistance, 757
Enterobacteriaceae, 1362
gram-negative-bacterial infections, 1362
K. pneumoniae, 693
resistance, 757, 1451, 1915
meningitis, 693
N. meningitidis, 1622
P. aeruginosa, 526, 1362
exoenzymes, 41
pharmacokinetics, 693
Streptococcus spp., 580
Ceftetrame
C. pylori, 1650
Ceftibuten
C. jejuni, 781
comparative activity
ampicillin, ceftriaxone, chloramphenicol, ciprofloxacin, and trimethoprim-sulfamethoxazole, 781
Enterobacteriaceae, 781
H. influenzae, 1878
Ceftizoxime
B. fragilis group, 394
E. coli, 35, 382
K. pneumoniae, 35
N. meningitidis, 1622
S. aureus, 35
serum ultrafiltrate, 35
Ceftriaxone
B. avium, 771
B. bronchiseptica, 771
biliary excretion
diclofenac, 1506
combinations
E. coli, 767
endocarditis, 767
netilmicin, 767
E. coli, 35, 767
endocarditis, 767
K. pneumoniae, 35
N. gonorrhoeae, 164, 233
N. meningitidis, 1622
open-heart surgery, 850
P. aeruginosa, 35
pharmacokinetics, 850
S. aureus, 35
serum ultrafiltrate, 35
Cefuroxime
B. avium, 771
B. bronchiseptica, 771
β-lactamase, 1313
C. pylori, 1650
E. coli, 382
Enterobacteriaceae, 1313
N. meningitidis, 1622
P. multocida, 2142
shunt infections
ventricular fluid concentrations, 1108
Cefuroxime axetil
comparative activity
amoxicillin-probenecid, 801
cefaclor, 1212
gonococcal infections, 801
urinary tract infections, 1212
Cephalexin
B. parapertussis, 968
β-lactamase, 1313
combinations
aluminum magnesium hydroxide, 1901
bioavailability, 1901
pirenzepine, 1901
ranitidine, 1901
Enterobacteriaceae, 1313
P. multocida, 2142
pharmacokinetics, 1901
Cephaloridine
P. aeruginosa
outer membrane permeability, 1201
Cephalosporinase
C. freundii
E1040, 2157
Cephalosporins
β-lactamases, 951, 1958
E. coli, 757
salicylate medium, 412
gram-negative bacteria, 35
gram-negative bacteria, resistant
cefepime, 498
K. pneumoniae resistance, 757
minireview, 407
P. shigelloides, 1609
paralysis, soft tissue penetration in, 1326
serum ultrafiltrate, 35
Staphylococcus spp., 407
Cephalothin
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
E. coli, 382
M. leprae, 657
cfxB
characterization, 283
CGP 31608
autolysins, 1819
Chancroid
fleroxacin, 612
Chemostat system
biofilm bacterium-antibiotic interaction, 1824
Chlamydia pneumoniae
azithromycin, 1634
ciprofloxacin, 1634
clarithromycin, 1634
erythromycin, 1634
roxithromycin, 1634
sulfamethoxazole, 1634
tetracycline, 1634
Chlamydia spp.
AT-4140, 1167
Chlamydia trachomatis
BMY 40062, 906
fleroxacin
adverse reactions, 1778
dose-ranging study, 1774, 1778
genital infections, 1774, 1778
lomefloxacin, 2049
pristinamycin, 2152
rifabutin, 1393
rifampin
resistance, 1393
temafloxacin, 118
Chloramphenicol
A. viridans resistance, 529
B. avium, 771
B. bronchiseptica, 771
B. fragilis group, 394
B. parapertussis, 968

Clostridium spp.
resistance determinant analysis, 1569
M. leprae, 657
N. meningitidis, 1622
P. cepacia resistance, 136
Cholera
furazolidone, 1447
tetracycline, 1447
Choleresis
cefmetazole, 1970
Chromatin
cleavage and degradation
bleomycin, 1592
growth phase dependency, 1592
S. cerevisiae, 1592
CI-934
E. coli
DNA gyrase, 1816
Enterococcus spp., 71
topoisomerase II, 1816
Cilofungin
Aspergillus spp., 1391
B. dermatitidis, 1391
C. albicans, 1822
C. neoformans, 1391
Candida spp., 1391
candidiasis, 1811
comparative activity
amphotericin B, 1811, 1822
endocarditis, 1822
Malassezia spp., 1391
P. brasiliensis, 1391
susceptibility testing
medium, 731
pH, 731
T. glabrata, 1391
Cimetidine
rimantadine disposition, 820
Cinoxacin
C. pylori, 108
E. gracilis, 1883
mycoplasmas, 103
Ciprofloxacin
A. faecalis
DNA synthesis, 1457
uptake, 1457
absorption
ferrous sulfate, 1841
multivitamins with zinc, 1841
Acinetobacter spp., 1617
B. melitensis, 1409
bioavailability
nasogastric tube administration, 1118
C. burnetii, 1052
C. pneumoniae, 1634
C. pylori, 108
caffeine disposition, 474
combinations
endocarditis, 1184
fever in neutropenic patients, 87
netilmicin, 87
rifampin, 181, 1184
S. aureus, 181, 1184
comparative activity
amikacin and imipenem, 176
ciprofloxacin-rifampin, rifampin, and vancomycin, 1184
cortisol concentrations, 1875
E. coli, 1184
DNA gyrase, 1816
DNA synthesis, 1457
P fimbriae, 684
uptake, 1457
E. gracilis, 1883
elimination
rifampin, 589
endocarditis, 1184
Enterococcus spp., 71
high-performance liquid chromatography, 1927
high-pressure liquid chromatography, 1841
L. interrogans serogroup icterohaemorrhagiae, 788
letter to the editor, 595
liposomes, 1379
M. avium complex, 176
M. leprae, 657
Mediterranean spotted fever, 987
minireview, 1
Mycobacterium spp., 1
mycoplasmas, 103
N. meningitidis, 1622
nasogastric tube administration
pharmacokinetics, 1118
oropharyngeal flora, 1645
P. aeruginosa, 526, 1368
accumulation, 1921
DNA synthesis, 1457
exoenzymes, 41
mutants, 124
uptake, 1457
P. shigelloides, 1609
paraxanthine disposition, 474
pharmacokinetics, 1645, 1841
age, 1927
caffeine, 474
nasogastric tube administration, 1118
S. aureus, 128
resistance, 593
Staphylococcus spp., 209
testosterone concentrations, 1875
topoisomerase II, 1816
transmembrane diffusion, 1379
urinary tract infections
resistance, 595
Ciprofloxacin-netilmicin
comparative activity
piperacillin-netilmicin, 87
fever in neutropenic patients, 87
Cisplatin
nephrotoxicity
fosfomycin protective effect, 513
piperacillin protective effect, 513
Citrobacter freundii
β-lactamase, 398
6-aminopenicillanic acid induction, 1116
E. coli penicillin-binding protein, 1116
cefotaxime, 398
cefotiam, 398
cefpirome, 398
ceftazidime, 398
cephalosporinase
E1040, 2157
E1040, 2157
ME1228, 1260
QA-241, 1144
Citrobacter spp.
AM-1091, 1036
BRL 42715, 1580
cefepime, 498
cephalosporin resistance, 498
FK482, 1795
Clarithromycin
analogs
S. pyogenes, 78
C. pneumoniae, 1634
comparative activity
amikacin, ciprofloxacin, difloxacin, erythromycin, ethambutol, rifampin, and temafloxacin, 1531
M. avium complex, 1531, 1614
M. leprae, 657, 2115
M. tuberculosis, 591
pharmacokinetics, 751
Clavulanic acid
Acinetobacter spp., 1617
comparative activity
piperacillin, piperacillin-tazobactam, tazobactam, ticarcillin, ticarcillin-clavulanate, 1268
Clindamycin
B. fragilis group, 394
combinations
rifampin, 245
Staphylococcus spp., 245
comparative activity
cefazolin, 1760
M. leprae, 657
osteomyelitis, 1760
S. aureus, 1760
Staphylococcus spp., 245
Clindamycin phosphate
pharmacokinetics, 618
Clinical trials
editorial, 1829
guidelines, 1829
Clofazimine
analogs
M. leprae, 657
M. leprae, 657, 2115
Clorobiocin
E. gracilis, 1883
Clostridium butyricum
β-lactamase, 1302
Clostridium difficile
BMY 40062, 906
cat, 1569
disease, associated
teicoplanin, 1125
vancomycin, 1125
SKF104662, 560
teicoplanin, 1125
vancomycin, 1125
Clostridium perfringens
AT-4140, 1167
cat, 1569
macrolide-lincosamide-streptogramin B resistance determinant
cloning and hybridization, 1346
Clostridium spp.
chloramphenicol
resistance determinant analysis, 1569
SM-7338, 215
Clotrimazole
skin infections, 970
vaginosis, bacterial, 970
Cloxacillin
M. leprae, 657
S. aureus
cyclophosphamide pretreatment, 980
Colds
R61837, 522
Colon surgery
cefoperazone prophylaxis, 835
Colorectal surgery
imipenem pharmacokinetics, 204
imipenem-cilastatin, 204

Coronavirus
7-thia-8-oxoguanosine, 1487
Cortisol
ciprofloxacin, 1875
Corynebacterium group JK
daptomycin, 1783
daptomycin-amikacin, 1783
Corynebacterium jeikeium
Ro 23-9424, 944
Coumarins
E. gracilis
chloroplast elimination, 1883
Coumermycin
Enterococcus spp., 71
Coumermycin A_1
E. gracilis, 1883
Coxiella burnetii
ciprofloxacin, 1052
difloxacin, 1052
doxycycline, 1052
norfloxacin, 1052
ofloxacin, 621, 1052
pefloxacin, 621, 1052
rifampin, 1052
Coxsackievirus
WIN 54954, 2069
CP-63,956
E. histolytica, 960
CP-65,207
β-lactamases, 1160
comparative activity
cefotaxime, cefoxitin, ceftazidime, imipenem, and methicillin, 1160
E. faecalis, 1160
Enterobacteriaceae, 1160
gram-positive organisms, 1160
P. aeruginosa, 1160
penicillin-binding protein affinity, 1160
Peptococcus spp., 1160
S. marcescens, 1160
Staphylococcus spp., 1160
Streptococcus spp., 1160
CP-67,015
topoisomerase II assays, 1697
Cranberry juice
E. coli adherence, 92
Cryptococcosis
murine
SCH39304, 1242
SCH39304, 1735
Cryptococcus neoformans
amphotericin B, liposomal, 345
cilofungin, 1391
liposomal amphotericin B, 345
meningitis, 1735
piritetrate, 2118
SCH39304, 1735
2′-nor-Cyclic GMP
comparative activity
acyclovir, 1600
cytomegalovirus
guinea pig, 1563
guinea pig lymphotropic herpesvirus, 1600
Cyclophosphamide
pretreatment
cloxacillin, 980
erythromycin, 980
S. aureus, 980
D-Cycloserine
M. leprae, 657
Cystic fibrosis
P. aeruginosa, 526
Cystitis
ofloxacin, 1308
trimethoprim-sulfamethoxazole, 1308
Cytomegalovirus
antibody activity-containing ascitic fluid, 1975
ara-sangivamycin–adenosine, 1606
3′-azido-3′-deoxythymidine-phosphonoformate, 663
ganciclovir, 1975
guinea pig
2′-nor-cyclic GMP, 1563
9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine phosphate-oxide, 1563
retinitis
acquired immunodeficiency syndrome, 736
foscarnet, 736
zidovudine-foscarnet, 663

Dactimicin
aminoglycoside-modifying enzymes, 1998
comparative activity
amikacin, gentamicin, netilmicin, and tobramycin, 1998
E. agglomerans, 1998
E. coli, 1998
Enterobacteriaceae, 1998
K. pneumoniae, 1998
P. aeruginosa, 1998
S. aureus, 1998
S. marcescens, 1998
Salmonella spp., 1998
Staphylococcus spp., 1998
Yersinia spp., 1998
Dapsone
M. leprae, 657, 2115
Daptomycin
combinations
amikacin, 1783
Corynebacterium group JK, 1783
E. faecalis, 470, 1198, 1783
fosfomycin, 470
gentamicin, 1198
S. aureus, 1198
Staphylococcus spp., 1783
tobramycin, 1280
comparative activity
ampicillin, ampicillin-sulbactam, imipenem, and vancomycin, 1019
ampicillin, cefotaxime, cefoxitin, clindamycin, erythromycin, gentamicin, penicillin G, and vancomycin, 1383
ampicillin-gentamicin, cefazolin, penicillin-streptomycin, and vancomycin, 1522
daptomycin-gentamicin, gentamicin, nafcillin, penicillin G, penicillin G-gentamicin, vancomycin, and vancomycin-gentamicin, 1198
fusidic acid, rifampin, teicoplanin, and vancomycin, 585
vancomycin, 689, 1280, 1783
Corynebacterium group JK, 1783
E. faecalis, 251, 470, 1019, 1522, 1783
postantibiotic effect, 1198
E. faecium, 10
endocarditis, 1019, 1522
killing rates, 1783
Lactobacillus spp., 1383
Leuconostoc spp., 1383
nephrotoxicity, 1280
osteomyelitis, 689
Pediococcus spp., 1383
postantibiotic effect
E. faecalis, 1198
S. aureus, 1198
S. aureus, 689, 1280
postantibiotic effect, 1198
S. epidermidis, 585
S. haemolyticus, 585
serum bactericidal titers, 1783
Staphylococcus spp., 1522, 1783
letter to the editor, 1652
surface colonizing, 813
susceptibility testing, 1652
Streptococcus spp., 1522
susceptibility testing, 585
letter to the editor, 1652
Staphylococcus spp., 1652
tobramycin nephotoxicity, 1280
9-Deazainosine
T. b. brucei, 881
T. b. evansi, 881
3-Deazaneplanocin A
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 1291
vesicular stomatitis virus, 1291
Dental plaque bacteria
N,N′-dialkylpolymethylenediamines, 1636
Deoxyfructoserotonin
M. leprae
Schwann cell uptake, 866
Dextran sulfate
human immunodeficiency virus type 1 reverse transcriptases, 115
DHCA
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 1291
vesicular stomatitis virus, 1291
DHCDA
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 1291
vesicular stomatitis virus, 1291
N,N′-Dialkylpolymethylenediamines
Actinomyces spp., 1636
dental plaque bacteria, 1636
oral bacteria, 1636
Streptococcus spp., 1636
2,4-Diaminoquinazolines
dihydrofolate reductase, 1860
Leishmania spp., 1860
Diclofenac
ceftriaxone biliary excretion, 1506
Dicloxacillin
S. aureus
catheter coating, 1174
2′,3′-Dideoxycytidine
bone marrow toxicity, 576
combinations
3′-azido-3′-deoxythymidine, 920
human immunodeficiency virus, 920
human immunodeficiency virus, 576
simian acquired immunodeficiency syndrome, 1908

simian retrovirus type 2, 1908
2',3'-Dideoxy-2',3'-didehydrothymidine
cellular pharmacology, 844
metabolism, 844
2'-3'-Dideoxynucleosides
comparative activities
duck hepadnavirus, 336
Diffusion coefficients
measurement, 1286
Difloxacin
B. melitensis, 1409
C. burnetii, 1052
Enterococcus spp., 71
gonorrhea, 1721
M. tuberculosis, 591
mycoplasmas, 103
DL-α-(Difluoromethyl)ornithine hydrochloride monohydrate
T. b. brucei, 881
T. b. evansi, 881
Dihydrofolate reductase
combinations
sulfonamides, 1753
T. gondii, 1753
2,4-diaminoquinazolines, 1860
folate analogs, 1860
Leishmania spp., 1860
P. cepacia, 1247
T. gondii, 1753
Dihydropteroate synthase
E. coli, 1936
P. aeruginosa, 1936
phosphanilic acid, 1936
9-(*trans*-2',*trans*-3'-Dihydroxycyclopent-4'-enyl)-adenine
S-adenosylhomocysteine, 828
murine cell growth, 828
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 828, 1291
vesicular stomatitis virus, 1291
9-(*trans*-2',*trans*-3'-Dihydroxycyclopent-4'-enyl)-3-deazaadenine
S-adenosylhomocysteine, 828
murine cell growth, 828
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 828, 1291
vesicular stomatitis virus, 1291
Dirithromycin
C. pylori, 1650
DNA hybridization
M. tuberculosis, 1000
DNA polymerase gamma
azidothymidine triphosphate, 2109
DNA probes
AAC(3)-I resistance gene, 551
S. haemolyticus, 460
DNA topoisomerases
minireview
biochemical characteristics, 2027
physiological significance, 2027
Doxycycline
Acinetobacter spp., 1617
C. burnetii, 1052
cerebrospinal fluid concentrations
Lyme disease, 1078
combinations
aluminum magnesium hydroxide, 1901
bioavailability, 1901
pirenzepine, 1901
ranitidine, 1901
G. lamblia, 2144
Lyme disease
cerebrospinal fluid concentrations, 1078
Mediterranean spotted fever, 987
pharmacokinetics, 1901
antacids, 434
Duck hepadnavirus
2',3'-dideoxynucleosides
purine, 336
pyrimidine, 336
Dyspepsia, nonulcerative
C. pylori, 256
norfloxacin, 256

E1040
C. freundii
cephalosporinase, 2157
comparative activity
cefotaxime and ceftazidime, 2157
Echovirus
WIN 54954, 2069
Editorial
clinical trials guidelines, 1829
Electronic counting
postantibiotic effect, 2155
Elfamycins
E. coli
elongation factor Tu, 322
protein synthesis, 322
elongation factor Tu
E. coli, 322
S. aureus, 322
S. aureus
elongation factor Tu, 322
protein synthesis, 322
structure-activity relationships, 322
Ellipticine
topoisomerase II assays, 1697
Elongation factor Tu
E. coli, 322
elfamycins, 322
S. aureus, 322
Encephalomyocarditis virus
7-thia-8-oxoguanosine, 1487
Endocarditis
ampicillin, 1019
ampicillin-sulbactam, 1019
C. albicans, 1735, 1822
ceftriaxone, 767
ceftriaxone-netilmicin, 767
cilofungin, 1822
ciprofloxacin, 1184
ciprofloxacin-rifampin, 1184
daptomycin, 1019, 1522
E. coli, 767
E. faecalis, 1019, 1522
Enterococcus spp., 1329
fleroxacin, 519
gram-positive cocci, 871
imipenem, 1019
netilmicin, 767
netilmicin-ceftriaxone, 767
rifampin, 1184
rifampin-ciprofloxacin, 1184
S. aureus, 519, 1184
SCH39304, 1735
Staphylococcus spp., 1329, 1522
Streptococcus spp., 1522
teicoplanin, 871, 1329
teicoplanin-aminoglycoside, 871
vancomycin, 1019, 1184
Endophthalmitis
C. albicans, 1735
SCH39304, 1735
Endotoxin
vancomycin
intrarenal distribution, 1575
pharmacokinetics, 1575
Enoxacin
C. pylori, 108
combinations
interleukin-1α, 1804
K. pneumoniae, 1804
P. aeruginosa, 1804
dosage comparison, 877
E. coli, 877
DNA gyrase, 1816
E. gracilis, 1883
Enterococcus spp., 71
liposomes, 1379
M. tuberculosis, 591
mycoplasmas, 103
N. gonorrhoeae, 233
P. aeruginosa, 1804
pharmacokinetics
antacids, 615
ranitidine, 615
Staphylococcus spp., 877
topoisomerase II, 1816
transmembrane diffusion, 1379
urinary tract infection, 877
Enpiroline
crystal and molecular structure, 1081
Entamoeba histolytica
azithromycin, 960
CP-63,956, 960
erythromycin, 960
metronidazole, 960
Enteritis
C. jejuni
early treatment, 248
erythromycin, 248
trimethoprim-sulfamethoxazole, 248
Enterobacter agglomerans
dactimicin, 1998
Enterobacter cloacae
β-lactamase
AmpC, *ampG* essential for, 1946
BMY-28232, 489
outer membrane proteins, 937
pefloxacin
resistance selection, 937
peritonitis, 937
Enterobacter spp.
AM-1091, 1036
BRL 42715, 1580
cefepime, 498
cephalosporin resistance, 498
FK482, 1795
ME1228, 1260
Enterobacteriaceae
AM-1091, 1036
amifloxacin, 762, 1837
metabolites, 762
AT-4140, 1167
BMY 40062, 906
BO-1341, 1423
BRL 42715, 1580
cefaclor, 1313
cefepime, 498
cefixime, 1313
ceftazidime, 1362
ceftibuten, 781

cefuroxime, 1313
cephalexin, 1313
cephalosporin resistance, 498
CP-65,207, 1160
dactimicin, 1998
gentamicin resistance
aacC2 sequence, 1153
ME1228, 1260
S-ofloxacin, 1105
outer membrane mutants
amifloxacin, 1837
resistance, spontaneous, 1837
pefloxacin, 1362
2-phenyl-1,2-benzoisoselenazol-3(2*H*)-one, 1388
PZ51, 1388
Ro 23-9424, 944, 1072
SM-7338, 215, 562, 1009, 1232
Enterococcus faecalis
AM-1091, 1036
ampicillin, 1019
ampicillin-sulbactam, 251, 1019
β-lactamases, 251, 1019
CP-65,207, 1160
daptomycin, 251, 470, 1019, 1522, 1783
postantibiotic effect, 1198
daptomycin-amikacin, 1783
daptomycin-fosfomycin, 470
endocarditis, 871, 1019, 1522
FK482, 1795
fosfomycin, 470
fosfomycin-daptomycin, 470
imipenem, 1019
postantibiotic effect, 1714
KB-5246, 1896
norfloxacin
postantibiotic effect, 1714
penicillin-gentamicin
postantibiotic effect, 608
QA-241, 1144
teicoplanin, 251, 871, 1588
vancomycin, 251, 1019
resistance, 198, 1121, 1588
susceptibility testing, 1588
Enterococcus faecalis subsp. *liquefaciens*
AS-48, 641
Enterococcus faecium
daptomycin, 10
macrolide-lincosamide-streptogramin B-type antibiotics, 10
R plasmids, 10
teicoplanin
resistance, transferable, 10
vancomycin resistance, 1121
transferable, 10
Enterococcus spp.
A-56620, 71
amifloxacin, 71
AT-4140, 1167
BMY 40062, 906
CI-934, 71
ciprofloxacin, 71
coumermycin, 71
difloxacin, 71
endocarditis, 1329
enoxacin, 71
letters to the editor, 989, 1411, 2164
ME1228, 1260
norfloxacin, 71
penicillin-aminoglycoside resistance, 71
Ro 23-9424, 944, 1072
SKF104662, 560
SM-7338, 562
teicoplanin, 1329, 1477, 2019
trimethoprim-sulfamethoxazole, 989
vancomycin, 1477, 2019
derivatives, 1477
Enterovirus
WIN 54954, 2069
Epidermophyton floccosum
imidazole analogs, 895
triazole analog, 895
Epileptogenicity
quinolones, 1704
Ergosterol
transport, 2092
ermP
cloning and hybridization, 1346
Erythrocytes, human
amphotericin B, 152
liposomal, 152, 345
potassium leakage, 152
amphotericin B-gramicidin S, 152
liposomal, 152
potassium leakage, 152
gramicidin S, 152
liposomal, 152
potassium leakage, 152
gramicidin S-amphotericin B, 152
liposomal, 152
potassium leakage, 152
liposomal amphotericin B, 345
Erythromycin
A. viridans resistance, 529
analogs
S. pyogenes, 78
B. avium, 771
B. bronchiseptica, 771
B. catarrhalis
resistance, 1631
B. fragilis
accumulation by, 242
B. parapertussis, 968
C. jejuni, 248
C. pneumoniae, 1634
C. pylori, 108, 1650
E. coli
resistance, 1354
E. histolytica, 960
enteritis, 248
hydrophobicity, 242
M. leprae, 657
6-*O*-methyl-11,12-cyclic carbamate derivatives
macrolide-lincosamide-streptogramin B-resistant ribosomes, binding to, 1058
minireview, 791
ototoxicity, 791
pharmacokinetics, 751
S. aureus
cyclophosphamide pretreatment, 980
S. haemolyticus resistance, 460
Erythromycin A
glycosylation by *S. vendargensis*
2′-(*O*-[β-D-glucopyranosyl])erythromycin A, 2089
Erythromycylamine
M. avium complex, 1614
Escherichia coli
adherence to eucaryotic cells
cranberry juice, 92
AM-1091, 1036
amifloxacin, 1837
amikacin
postantibiotic effect, 1714
aminoglycosides
tet expression, 1549
tetracycline resistance gene, 230
amoxicillin
N-formyl peptide conjugate, 1516
amoxicillin-clavulanate resistance, 595
ampicillin, 382
bactericidal activity determinants, 1046
N-formyl peptide conjugates, 1516
AT-4140, 1167
DNA gyrase, 1980
3′-azido-3′-deoxythymidine, 479
aztreonam, 382
β-lactamases, 382, 757, 1958
β-lactams, 382
peptidoglycan synthesis, 2101
bismuth subsalicylate
ATP, 2075
binding and killing, 2075
BMY-28232, 489
cefepime, 382
cefoperazone, 35, 382
cefotaxime, 382
cefoxitin, 382
cefpirome, 382
ceftazidime, 382
resistance, 757
ceftizoxime, 35, 382
ceftriaxone, 35, 767
ceftriaxone-netilmicin, 767
cefuroxime, 382
cephalosporin uptake
salicylate medium, 412
cephalosporins
resistance, 757
cephalothin, 382
cfxB, 283
ciprofloxacin, 684
DNA synthesis, 1457
uptake, 1457
dactimicin, 1998
dihydropteroate synthase, 1936
DNA gyrase
A gene, 886
amifloxacin, 1837
AT-4140, 1980
quinolones, 1816
elfamycins
elongation factor Tu, 322
protein synthesis, 322
structure-activity relationships, 322
endocarditis, 767
enoxacin, 877
erythromycin
resistance, 1354
FK482, 1795
fleroxacin, 684
resistance, 239
flomoxef, 382
fluoroquinolones
P fimbriae, 684
gentamicin
hyperoxia, 1526
tetracycline resistance gene, 230
glycopeptide susceptibility, 192
gyrA and *gyrB* mutations, 254
hyperoxia and susceptibility, 1526
imipenem, 382
postantibiotic effect, 1714
letter to the editor, 595
macrolide 2′-phosphotransferase, 1354
moxalactam, 35, 382

multiply antibiotic resistant
fluoroquinolone cross resistance, 1318
membrane changes, 1318
OmpF reduction, 1318
mupirocin transport, 156
nalidixic acid, 684
netilmicin, 767
netilmicin-ceftriaxone, 767
nfxB, 283
nitrofurantoin
hyperoxia, 1526
norfloxacin, 684
postantibiotic effect, 1714
ofloxacin, 1308
omp mutation, 382
P fimbriae
fluoroquinolones, 684
penicillin-binding proteins, 2101
C. freundii β-lactamase induction by 6-aminopenicillanic acid, 1116
peptidoglycan synthesis
β-lactamases, 2101
β-lactams, 2101
phosphanilic acid, 1936
piperacillin, 382
piperacillin-tazobactam, 1964
plasmids, 595, 757, 1958, 2042
QA-241, 1144
quinolone
resistance, 254, 283, 886
tolerance, 705
R plasmid, 535
salicylate medium
cephalosporin uptake, 412
sodium hexametaphosphate
outer membrane disruption, 1741
sulfamethoxazole
hyperoxia, 1526
sulfathiazole resistance
gene amplification, 2042
sulfonamide resistance
gene amplification, 2042
TEM-4, 1958
tet
aminoglycoside uptake, 1549
tetracycline resistance gene
gentamicin killing, 230
tobramycin
hyperoxia, 1526
trimethoprim, 684
hyperoxia, 1526
trimethoprim-sulfamethoxazole, 1308
urinary tract infection, 877
uropathogenic
fluoroquinolones, 684
zidovudine, 479
Ethambutol
M. smegmatis
arabinogalactan synthesis, 1493
Ethionamide
M. leprae, 657, 2115
Etoposide
granulocytopenia, 980
monocytopenia, 980
S. aureus, 980
Euglena gracilis
chloroplast elimination
coumarins, 1883
quinolones, 1883
cinoxacin, 1883
ciprofloxacin, 1883
clorobiocin, 1883
coumarins
chloroplast elimination, 1883
coumermycin A_1, 1883
enoxacin, 1883
nalidixic acid, 1883
norfloxacin, 1883
novobiocin, 1883
ofloxacin, 1883
oxolinic acid, 1883
quinolones
chloroplast elimination, 1883
Exoenzymes
P. aeruginosa, 41
Exoprotease
A. salmonicida, 19
Extracorporeal membrane oxygenation
gentamicin pharmacokinetics, 817

Famciclovir
BRL 39123 oral prodrug, 1765
pharmacokinetics, 1765
Fatty acids
P. aeruginosa
polymyxin B resistant, 1724
FCE 22101
S. aureus, 120
Feeder layer-free screen
T. b. brucei, 881
T. b. evansi, 881
Feline immunodeficiency virus
3′-azido-3′-deoxythymidine, 915
model for acquired immune deficiency syndrome chemotherapy, 915
reverse transcriptase, 915
Fenticonazole
bacterial vaginosis, 970
comparative activity
clotrimazole, metronidazole, miconazole, and tetracycline, 970
skin infections, 970
vaginosis, bacterial, 970
Ferrous sulfate
ciprofloxacin absorption, 1841
FK482
Bacteroides spp., 1795
β-lactamases, 1795
Citrobacter spp., 1795
comparative activity
amoxicillin-clavulanate, cefixime, cefuroxime, and cephalexin, 1795
E. coli, 1795
E. faecalis, 1795
Enterobacter spp., 1795
H. influenzae, 1795
K. pneumoniae, 1795
Morganella spp., 1795
N. gonorrhoeae, 1795
P. mirabilis, 1795
P. vulgaris, 1795
Providencia spp., 1795
Pseudomonas spp., 1795
S. aureus, 1795
Salmonella spp., 1795
Serratia spp., 1795
Shigella spp., 1795
Streptococcus spp., 1795
Flavobacterium spp.
AT-4140, 1167
Fleroxacin
C. pylori, 108
C. trachomatis
adverse reactions, 1778
dose-ranging study, 1774, 1778
chancroid, 612
combinations
gentamicin, 2037
oxacillin, 2037
rifampin, 2037
Staphylococcus spp., 2037
vancomycin, 2037
comparative activity
vancomycin, 519
E. coli
DNA gyrase, 1816
P fimbriae, 684
resistance, 239
endocarditis, 519
fluorometric assay, 27
genital infections, 1774, 1778
mycoplasmas, 103
pharmacokinetics
renal function, 373
S. aureus, 519
topoisomerase II, 1816
Flomoxef
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
E. coli, 382
Fluconazole
C. albicans, 147, 1042
Candida spp., 1443
candidiasis, 1042
comparative activity
amphotericin B, 1042, 1443
amphotericin B and itraconazole, 147
gas-liquid chromatography, 714
high-pressure liquid chromatography, 467
pharmacokinetics, 467, 714, 963
sputum levels, 963
tissue penetration, 467
W. dermatitidis, 1639
Flucytosine
Aspergillus spp.
metabolism, 1939
nuclear magnetic resonance spectroscopy, 1939
bioassays, 1403
Fusarium spp., 1647
high-performance liquid chromatography, 1403
W. dermatitidis, 1639
Fluorescence polarization immunoassay
zidovudine, 1275
Fluorometric assays
fleroxacin, 27
fluoroquinolone penetration, 653
ofloxacin uptake by human polymorphonuclear leukocytes, 653
quinolones, 27
5-Fluoroorotic acid
comparative activity
5-fluorouracil, 5-fluorouridine, and 5-fluoro 2′-deoxyuridine, 1090
P. falciparum, 1090
toxicity, 1090
Fluoroquinolones
adverse effects
genital infections, 1662
minireview, 1662
C. pylori, 108
E. coli
cross resistance, 1318
E. coli, uropathogenic

P fimbriae, 684
fluorometric assay, 653
genitourinary tract infections
minireviews, 1655, 1662
M. tuberculosis, 591
minireviews, 131, 1655, 1662
pharmacokinetics
minireview, 1655
prostatitis, 1655
urinary tract infections, 1655
prostatitis
minireview, 1655
S. aureus resistance
norA gene, 1535
structure-activity relationships, 131
urinary tract infections
minireview, 1655
Flusilazole
lanosterol 14α-methyl demethylase
mammalian, 1228
yeast, 1228
Folate
2,4-diaminoquinazoline analogs
Leishmania spp., 1860
Formicin
T. b. brucei, 881
T. b. evansi, 881
Foscarnet
acquired immunodeficiency syndrome, 736
combinations
3′-azido-3′-deoxythymidine, 663, 778
human immunodeficiency virus, 778
human immunodeficiency virus type 1, 663
zidovudine, 663
cytomegalovirus, 663
retinitis, 736
high-pressure liquid chromatography, 742
human immunodeficiency virus
pharmacokinetics, 1023
pharmacokinetics
cytomegalovirus retinitis, 742
human immunodeficiency virus, 1023
retinitis, cytomegalovirus, 736
Fosfomycin
combinations
daptomycin, 470
E. faecalis, 470
E. faecalis, 470
Fungi
piritetrate, 2118
Furazolidone
cholera, 1447
comparative activity
tetracycline, 1447
Fusarium spp.
amphotericin B, 1647
flucytosine, 1647
itraconazole, 1647
miconazole, 1647
natamycin, 1647
Fusidic acid
human immunodeficiency virus, 680
Fusobacterium spp.
cell-wall-defective variants, 369

γ-Aminobutyric acid receptors
quinolone epileptogenicity, 1704
Ganciclovir
combinations
antibody activity-containing ascitic fluid, 1975
cytomegalovirus, 1975
cytomegalovirus, 1975
herpes simplex virus
type 2, 635
Gardnerella vaginalis
pristinamycin, 2152
Gas-liquid chromatography
fluconazole, 714
Gastritis
C. pylori, 256
norfloxacin, 256
Genital infections
C. trachomatis, 1774, 1778
fleroxacin
adverse reactions, 1778
dose-ranging study, 1774, 1778
fluoroquinolones
minireview, 1662
Genitourinary tract infections
fluoroquinolones
minireviews, 1655, 1662
Gen-Probe DNA Hybridization System
M. tuberculosis, 1000
Gentamicin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
bactericidal activity
P. aeruginosa, 1553
peritoneal dialysis fluids, 1553
Staphylococcus spp., 1553
combinations
cefazolin, 1553
E. faecalis, 608
fleroxacin, 2037
interleukin-1α, 1804
K. pneumoniae, 1804
killing curve analysis, 1500
P. aeruginosa, 1500, 1553, 1804
penicillin, 608
peritoneal dialysis fluid bactericidal activity, 1553
piperacillin, 1500
postantibiotic effect, 608
serum bactericidal rate, 1500
Staphylococcus spp., 1553, 2037
E. coli
hyperoxia, 1526
tetracycline resistance gene, 230
Enterobacteriaceae resistance
aacC2 sequence, 1153
intracortical accumulation
age, 2006
M. leprae, 657
nephrotoxicity, 1890
ticarcillin protective effect, role of sodium in, 928
neutropenic patients, 1890
P. aeruginosa, 1804
hyperoxia, 1526
killing curve analysis, 1500
serum bactericidal rate, 1500
pharmacokinetics, 2006
extracorporeal membrane oxygenation, 817
neutropenic patients, 1890
surgical wounds, 700
S. epidermidis
resistance, 1335
S. haemolyticus resistance, 460
Staphylococcus spp., 209
resistance, 1335
surface colonizing, 813
Streptococcus spp., 580
uptake, intrarenal
indomethacin, influence of, 1342
Giardia lamblia
aminoglycosides, 484
apramycin, 484
doxycycline, 2144
hygromycin, 484
kanamycin, 484
paromomycin, 484
protein synthesis, 484
rRNA structure, 484
tetracyclines, 2144
thiacycline, 2144
L-Glutamine:keto-*scyllo*-inositol aminotransferase
aminocyclitol synthesis, 452
purification and characterization, 452
Glycopeptides
E. coli susceptibility, 192
Glycosylation
erythromycin A, 2089
S. vendargensis, 2089
Gnotobiotic animal model
R plasmid selection, 535
Gonococcal infections
amoxicillin-probenecid, 801
cefuroxime axetil, 801
Gonorrhea
amoxicillin-probenecid, 167
difloxacin, 1721
ofloxacin, 167
Gossypol
human immunodeficiency virus type 1
(−) and (+) enantiomers, 2149
T. b. brucei, 881
T. b. evansi, 881
Gramicidin S
combinations
amphotericin B, 152
C. albicans, 152
human erythrocytes, 152
liposomal
C. albicans, 152
human erythrocytes, 152
Gram-negative organisms
amikacin, 1137
aminoglycosides, 1137
AT-4140, 1167
aztreonam, 1137
bacteremia, 1855
ceftazidime, 1362
cephalosporins
serum ultrafiltrate, 35
norfloxacin, 1709
nosocomial isolates
resistance, 1855
pefloxacin, 1362, 1709
QA-241, 1144
resistance
nosocomial isolates, 1855
tobramycin, 1137
Gram-positive organisms
AT-4140, 1167
CP-65,207, 1160
norfloxacin, 1709
S-ofloxacin, 1105
pefloxacin, 1709
QA-241, 1144
SKF104662, 560, 965

Granulocytopenia
cyclophosphamide, 980
etoposide, 980
S. aureus, 980
Griseofulvin
M. leprae, 657
Guinea pig cytomegalovirus
2′-nor-cyclic GMP, 1563
9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine phosphate-oxide, 1563
Guinea pig lymphotropic herpesvirus
acyclovir, 1600
4-amino-5-bromo-7-(2-hydroxy-ethoxymethyl)pyrrolo(2,3-*d*)pyrimidine, 1600
2′-nor-cyclic GMP, 1600
9-[(2-hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine P-oxide, 1600
gyr
cloning and characterization, 886
E. coli mutants, 254

Haemophilus ducreyi
penicillin-binding proteins, 983
plasmids, 1611, 1627
Tet M, 1611
tetracycline resistance, 1611
Haemophilus influenzae
AM-1091, 1036
β-lactamases, 1878
BO-1341, 1423
cefixime, 1878
cefpodoxime, 1878
ceftibuten, 1878
FK482, 1795
penicillin-binding proteins, 1878
QA-241, 1144
Ro 23-9424, 944, 1072
SM-7338, 215
type b
ampicillin-sulbactam, 1620
β-Lactamase, 1620
Haemophilus spp.
AT-4140, 1167
SM-7338, 1009
Halothane
measles virus resistance, 400
Hematological malignancy
amikacin pharmacokinetics, 1406
β-lactam combinations, double, 503
bone marrow transplantation, 503
chemotherapy, 503
neutropenia, 503
Herpes genitalis
acyclovir, 649
interferon
alpha, 649
Herpes simplex virus
acyclovir, 649, 862
interferon, 1217
alpha, 649
liposomal, 1217
ribonucleotide reductase mutants
acyclovir hypersensitivity, 1395
aphidicolin hypersensitivity, 1395
phosphonoacetic acid hypersensitivity, 1395
type 1
A1110U, 1691
acyclovir, 223, 1691, 1864
acyclovir-A1110U, 1691
athymic mouse model, 304
BRL 39123, 223
(*S*)-HPMPA, 185
9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, 223
(*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 185
9-(2-phosphonylmethoxyethyl)adenine, 185, 1864
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, 185
PMEA, 185, 1864
PMEDAP, 185
5-substituted 2-pyrimidinone 2′-deoxyribonucleoside analogs, 340
type 2
acyclovir resistant, 635
ganciclovir, 635
(*S*)-HPMPA, 185
(*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 185
phosphonoacetic acid, 635
9-(2-phosphonylmethoxyethyl)adenine, 185
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, 185
PMEA, 185
PMEDAP, 185
5-substituted 2-pyrimidinone 2′-deoxyribonucleoside analogs, 340
R837, 1511
7-thia-8-oxoguanosine, 1487
Herpesviruses
acyclovir
high-dose continuous infusion, 1375
BRL 39123
oral prodrug, 1765
BRL 42810
BRL 39123 oral prodrug, 1765
famciclovir
BRL 39123 oral prodrug, 1765
penciclovir
oral prodrug, 1765
Hexametaphosphate, sodium
E. coli, 1741
outer membrane disruption, 1741
P. aeruginosa, 1741
Pseudomonas spp., 1741
Hexatroxanone
T. gondii, 1748
High-performance liquid chromatography
cefepime, 1326
cefixime, 1994
cefmetazole, 356
cefoxitin, 356
ciprofloxacin, 1927
flucytosine, 1403
norfloxacin, 99
ribavirin
comparative study, 311
teicoplanin, 1791
High-pressure liquid chromatography
amphotericin B, 362, 1989
carbovir, 171
cefoperazone, 857
cefotetan, 857
ciprofloxacin, 1841
fluconazole, 467
foscarnet, 742
N-methylthiotetrazole, 857
moxalactam, 857
ofloxacin, 1686
rifabutin, 1237
(*S*)-HPMPA
herpes simplex virus
type 1, 185
type 2, 185
vaccinia virus, 185
(*S*)-HPMPDAP
human immunodeficiency virus
type 1, 1482
Human immunodeficiency virus
3′-azido-3′-deoxythymidine, 920
3′-azido-3′-deoxythymidine alternating with 2′,3′-dideoxycytidine, 920
3′-azido-3′-deoxythymidine-foscarnet, 778
3′-azido-2′,3′-dideoxythymidine, 576
2′,3′-dideoxycytidine, 576
2′,3′-dideoxy-2′,3′-didehydrothymidine, 844
foscarnet
pharmacokinetics, 1023
foscarnet-3′-azido-3′-deoxythymidine, 778
fusidic acid, 680
oxetanocin, 773
reverse transcriptase, 778
rifabutin
pharmacokinetics, 1237
type 1
3′-azido-3′-deoxythymidine, 1482
3′-azido-3′-deoxythymidine-phosphonoformate, 663
3′-azido-3′-deoxythymidine–9-(2-phosphonylmethoxyethyl)adenine, 1482
3′-azido-2′,3′-dideoxyuridine-5′-triphosphate, 1729
AZT, 1482
AZT-PMEA, 1482
castanospermine-zidovudine, 53
dextran sulfate, 115
feline immunodeficiency virus model, 915
gossypol enantiomers, 2149
(*S*)-HPMPDAP, 1482
(*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine, 1482
nucleoside analogs-phosphonoformate, 2083
phosphonoformate-nucleoside analogs, 2083
9-(2-phosphonylmethoxyethyl)adenine, 1482
PMEA, 1482
reverse transcriptases, 115, 915, 1729
soap, 2034
suramin, 115
zidovudine-castanospermine, 53
zidovudine-foscarnet, 663
type 2
zidovudine-castanospermine, 53
zidovudine
bioequivalence of syrup, solution, and capsule, 1801
Human immunodeficiency virus type 1
reverse transcriptase, 2109
azidothymidine triphosphate, 2109
9-[(2-Hydroxy-1,3,2-dioxaphosphorinan-5-yl)oxymethyl]-guanine phosphate-oxide
comparative activity
acyclovir, 1600

cytomegalovirus
guinea pig, 1563
guinea pig lymphotropic herpesvirus, 1600
(*R*,*S*)-9[4-Hydroxy-2-(hydroxymethyl)butyl]guanine
pharmacokinetics, 110
salts and esters, 110
9-(4-Hydroxy-3-hydroxymethylbut-1-yl)guanine
comparative activity
acyclovir, 223
herpes simplex virus
type 1, 223
metabolism, 223
mode of action, 223
oral prodrug, 1765
pharmacokinetics, 1765
(*S*)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine
herpes simplex virus
type 1, 185
type 2, 185
vaccinia virus, 185
(*S*)-9-(3-Hydroxy-2-phosphonylmethoxypropyl)-2,6-diaminopurine
human immunodeficiency virus
type 1, 1482
Hygromycin
G. lamblia, 484
Hyperoxia
E. coli susceptibility, 1526
P. aeruginosa susceptibility, 1526

ICI 195,739
B. dermatitidis, 573
blastomycosis, 573
comparative activity
ketoconazole, 573
Imidazole analogs
A. fumigatus, 895
C. albicans, 895
Candida spp., 895
E. floccosum, 895
efficacy-safety profiles, 895
M. audouinii, 895
Trichophyton spp., 895
Imipenem
Acinetobacter spp., 1617
autolysins, 1819
B. fragilis group, 394
bactericidal activity
P. aeruginosa, 1553
peritoneal dialysis fluids, 1553
Staphylococcus spp., 1553
combinations
cilastatin, 204
colorectal surgery, 204
comparative activity
amikacin and ciprofloxacin, 176
ampicillin, ampicillin-sulbactam, daptomycin, and vancomycin, 1019
E. coli, 382
postantibiotic effect, 1714
E. faecalis, 1019
postantibiotic effect, 1714
endocarditis, 1019
M. avium complex, 176
N. meningitidis, 1622
P. aeruginosa
outer membrane permeability, 1201
postantibiotic effect, 1714
pharmacokinetics
colorectal surgery, 204
S. aureus
postantibiotic effect, 1714
Staphylococcus spp., 209
Streptococcus spp., 580
Indomethacin
gentamicin uptake, 1342
Indwelling medical devices
infections
extravascular, 602
intravascular, 597
minireviews, 597, 602
pathogenesis, 597
minireviews, 597, 602
Interferon
alpha
herpes genitalis, 649
herpes simplex virus, 649
murine acquired immunodeficiency disease, 1864
ocular, 396
alpha 2b
rhinovirus, postexposure phophylaxis of, 387
herpes simplex virus, 1217
liposomal
herpes simplex virus, 1217
Interferon, alpha
comparative activity
acyclovir, 649
Interleukin-1α
combinations
amphotericin B, 1804
C. albicans, 1804
ceftazidime, 1804
enoxacin, 1804
gentamicin, 1804
immunoglobulin, 1804
K. pneumoniae, 1804
miconazole, 1804
moxalactam, 1804
P. aeruginosa, 1804
Intestinal flora
cefoperazone, 835
Iontophoresis
bacterial concentration, 442
medium, 442
microamperage, 442
Isoniazid
M. leprae, 657
M. microti, 1255
mouse peritoneal macrophages, 1255
M. tuberculosis, 1000
Itraconazole
C. albicans, 147
comparative activity
amphotericin B and fluconazole, 147
Fusarium spp., 1647
W. dermatitidis, 1639

Josamycin
B. fragilis, accumulation by, 242
B. parapertussis, 968
hydrophobicity, 242

Kanamycin
comparative activity
amikacin, kanamycin, and streptomycin, 1298
G. lamblia, 484
M. avium, 1298
M. leprae, 657
M. tuberculosis, 1298
P. multocida
resistance, 670
KB-5246
comparative activity
ciprofloxacin, norfloxacin, and ofloxacin, 1896
E. faecalis, 1896
S. pneumoniae, 1896
S. pyogenes, 1896
Staphylococcus spp., 1896
Ketoconazole
W. dermatitidis, 1639
Klebsiella oxytoca
β-lactamase, 63
Klebsiella pneumoniae
AT-4140, 1980
aztreonam
resistance, 1451
β-lactamases, 757, 951, 2096
gene cloning, 2096
multiple, isolated at same hospital, 1915
SHV-3, 2096
SHV-5, 951
structure, 2096
TEM, 1915
TEM-10, 1451
cefoperazone, 35
cefotaxime
resistance, 2096
ceftazidime, 693
resistance, 757, 1451, 1915
ceftizoxime, 35
ceftriaxone, 35
cephalosporins
resistance, 757
dactimicin, 1998
FK482, 1795
interleukin-1α, 1804
interleukin-1α–enoxacin, 1804
interleukin-1α–gentamicin, 1804
interleukin-1α–immunoglobulin, 1804
interleukin-1α–moxalactam, 1804
meningitis, 693
moxalactam, 35, 1804
piperacillin-tazobactam, 1964
plasmids, 757, 951, 1915
QA-241, 1144
ticarcillin, 693
ticarcillin-clavulanic acid, 693
Klebsiella spp.
AM-1091, 1036

La Cross virus
ribavirin
mechanism of inhibition, 2009
Lactobacillus reuteri
reuterin
chemical characterization, 674
Lactobacillus spp.
daptomycin, 1383
spiramycin, 2016
teicoplanin, 1477
vancomycin, 1477
derivatives, 1477
Lanosterol 14α-methyl demethylases
flusilazole, 1228
mammalian, 1228
yeast, 1228

Legionella pneumophila
WIN 57273, 2132
Legionella spp.
AT-4140, 1167, 1980
Leishmania spp.
2,4-diaminoquinazolines, 1860
dihydrofolate reductase inhibitors, 1860
folate analogs, 1860
Leptospira interrogans serogroup icterohaemorrhagiae
ciprofloxacin, 788
Letters to the editor
amoxicillin-clavulanate resistance
E. coli, 595
plasmids, 595
catheter-related infections, 2023
ciprofloxacin resistance
urinary tract infections, 595
daptomycin
Staphylococcus spp., 1652
susceptibility testing, 1652
E. coli
amoxicillin-clavulanate resistance, 595
plasmids, 595
enterococcal infections, 989, 1411, 2164
trimethoprim-sulfamethoxazole, 989
intraluminal colonization, 2023
norfloxacin resistance
urinary tract infections, 595
plasmids
amoxicillin-clavulanate resistance, 595
E. coli, 595
susceptibility testing
daptomycin, 1652
Staphylococcus spp., 1652
trimethoprim-sulfamethoxazole
enterococcal infections, 989
urinary tract infections
ciprofloxacin resistance, 595
norfloxacin resistance, 595
Leuconostoc sp.
daptomycin, 1383
teicoplanin, 1477
vancomycin, 1477
derivatives, 1477
Lincomycin
β-lactamase mRNA, 805
E. coli, 805
Lipids
benzoyl peroxide
P. acnes, 326
Lipopolysaccharides
P. aeruginosa
polymyxin B binding, 1724
Liposomes
amikacin
M. avium complex, 1179
amphotericin B
antibody, attached, 16
C. albicans, 16, 152, 345
C. neoformans, 345
candidiasis, 1544
human erythrocytes, 152, 345
ciprofloxacin, 1379
composition, 345
enoxacin, 1379
gramicidin S
C. albicans, 152
human erythrocytes, 152
interferon
herpes simplex virus, 1217
rifampin
M. avium complex, 429
unilamellar vesicles, 345
Listeria monocytogenes
Ro 23-9424, 944
Listeria spp.
ME1228, 1260
Lomefloxacin
C. pylori, 108
C. trachomatis, 2049
Campylobacter spp., 1385
comparative activity
ceftriaxone, penicillin, spectinomycin, and tetracycline, 2049
ciprofloxacin, difloxacin, doxycycline, erythromycin, nalidixic acid, norfloxacin, temafloxacin, and trimethoprim-sulfamethoxazole, 1385
E. coli
DNA gyrase, 1816
mycoplasmas, 103
N. gonorrhoeae, 2049
Salmonella spp., 1385
Shigella spp., 1385
theophylline pharmacokinetics, 1006
topoisomerase II, 1816
Vibrio spp., 1385
Yersinia spp., 1385
Lyme disease
doxycycline, 1078

Macrolide 2'-phosphotransferase
E. coli, 1354
Macrolide-lincosamide-streptogramin B
E. faecium, 10
resistance determinant
C. perfringens, 1346
cloning and hybridization, 1346
ribosomes, resistant
6-*O*-methyl-11,12-cyclic carbamate erythromycin derivatives, binding of, 1058
S. aureus, 541
S. epidermidis, 541
S. pyogenes resistance, 78
Tn*554* insertion, 541
Macrolides
B. fragilis, accumulation by, 242
clinical efficacy
minireview, 1419
hydrophobicity, 242
in vitro activity
minireview, 1413
M. avium complex, 1614
minireviews
clinical efficacy, 1419
in vitro activity, 1413
pharmacokinetics, 1419
structural modifications, 1413
pharmacokinetics
minireview, 1419
structural modifications
minireview, 1413
Malaria
amopyroquin, 316
P. falciparum, 316
rodent
acridone alkaloids, 6
atalaphillinine, 6
Malassezia spp.
cilofungin, 1391
ME1228
β-lactamases, 1260
C. freundii, 1260
comparative activity
cefotaxime, ceftazidime, gentamicin, imipenem, and piperacillin, 1260
Enterobacter spp., 1260
Enterobacteriaceae, 1260
Enterococcus spp., 1260
Listeria spp., 1260
P. aeruginosa, 1260
S. aureus, 1260
S. pneumoniae, 1260
Staphylococcus spp., 1260
Streptococcus spp., 1260
X. maltophilia, 1260
Measles virus
halothane-resistant strain, 400
Mediterranean spotted fever
ciprofloxacin, 987
doxycycline, 987
pristinamycin, 2146
roxithromycin, 2146
Melanin
W. dermatitidis
antifungal susceptibility, 1639
Meningitis
C. neoformans, 1735
ceftazidime, 693
crytococcal
SCH39304, 1242
K. pneumoniae, 693
ofloxacin penetration, 933
pneumococcal
ampicillin, 418
dose, 418
dosing interval, 418
duration of therapy, 418
SCH39304, 1735
ticarcillin, 693
ticarcillin-clavulanic acid, 693
Methicillin
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
S. aureus resistance
low-level, 424
new mechanism, 1869
S. haemolyticus resistance, 460
Staphylococcus resistance
restriction map, 1624
N-Methylthiotetrazole
disposition
cefoperazone, 857
cefotetan, 857
moxalactam, 857
high-pressure liquid chromatography, 857
Metronidazole
B. fragilis group, 394
bacterial vaginosis, 970
E. histolytica, 960
skin infections, 970
vaginosis, bacterial, 970
Mezlocillin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
N. meningitidis, 1622
pharmacokinetics, 839
Miconazole
bacterial vaginosis, 970
combinations
C. albicans, 1804

interleukin-1α, 1804
Fusarium spp., 1647
skin infections, 970
vaginosis, bacterial, 970
Micrococcus sedentarius
endocarditis, 871
teicoplanin, 871
Micromonospora purpurea
L-glutamine:keto-*scyllo*-inositol aminotransferase, 452
Microsporum audouinii
imidazole analogs, 895
triazole analog, 895
Minireviews
aminoglycosides
ototoxicity, 797
β-lactamases
characterization, 259
classification, 264, 271
extended spectrum, 1131
cephalosporins
Staphylococcus spp., 407
ciprofloxacin
Mycobacterium spp., 1
DNA topoisomerases
biochemical characteristics, 2027
physiological significance, 2027
erythromycin
ototoxicity, 791
fluoroquinolones
adverse effects, 1662
genital infections, 1662
genitourinary tract infections, 1655, 1662
pharmacokinetics, 1655
prostatitis, 1655
structure-activity relationships, 131
urinary tract infections, 1655
genital infections
fluoroquinolones, 1662
genitourinary tract infections
fluoroquinolones, 1655, 1662
indwelling device infections
extravascular devices, 602
intravascular devices, 597
pathogenesis, 597
macrolide antibiotics
clinical efficacy, 1419
in vitro activity, 1413
pharmacokinetics, 1419
structural modifications, 1413
Mycobacterium spp.
ciprofloxacin, 1
norfloxacin, 1
ofloxacin, 1
pefloxacin, 1
quinolones, 1
norfloxacin
Mycobacterium spp., 1
ofloxacin
Mycobacterium spp., 1
ototoxicity
aminoglycosides, 797
erythromycin, 791
vancomycin, 791
outer membrane barrier, 1831
pefloxacin
Mycobacterium spp., 1
prostatitis
fluoroquinolones, 1655
quinolones
Mycobacterium spp., 1
resistance, 1831
Staphylococcus spp., methicillin resistant
detection, 995
genetics, 991
mechanisms of resistance, 991
treatment of infections, 995
topoisomerases, 2027
urinary tract infections
fluoroquinolones, 1655
vancomycin
ototoxicity, 791
Minocycline
A. viridans resistance, 529
B. parapertussis, 968
M. leprae, 657, 2115
Monocytopenia
cyclophosphamide, 980
etoposide, 980
S. aureus, 980
Moraxella lacunata
β-lactamase, 1845
Moraxella nonliquefaciens
β-lactamase, 1845
plasmids, 1845
Moraxella spp.
AT-4140, 1167
Moraxella subgenus *Moraxella*
β-lactamase, 1845
Morganella morganii
SM7338, 1232
Morganella spp.
FK482, 1795
piperacillin-tazobactam, 1964
SM-7338, 1009
Mouth lesions
acyclovir, 862
chemotherapy induced, 862
radiation induced, 862
Moxalactam
B. parapertussis, 968
combinations
clavulanic acid, 331
interleukin-1α, 1804
K. pneumoniae, 1804
S. aureus, 331
sulbactam, 331
E. coli, 35, 382
high-pressure liquid chromatography, 857
K. pneumoniae, 35, 1804
N-methylthiotetrazole disposition, 857
N. meningitidis, 1622
P. aeruginosa, 35
S. aureus, 35
serum ultrafiltrate, 35
Multivitamins with zinc
ciprofloxacin absorption, 1841
Mupirocin
burn wounds, 1358
S. aureus, 1358
transport mechanism
B. subtitis, 156
E. coli, 156
S. aureus, 156
Murine acquired immunodeficiency disease
azidothymidine, 1864
interferon
alpha, 1864
9-(2-phosphonylmethoxyethyl)adenine, 1864
PMEA, 1864
Murine cryptococcosis
SCH39304, 1242
Mycobacterium avium
amikacin, 1298
capreomycin, 1298
kanamycin, 1298
streptomycin, 1298
Mycobacterium avium complex
amikacin, 176, 1179
liposomal, 1179
ciprofloxacin, 176
clarithromycin, 1531, 1614
erythromycylamine, 1614
imipenem, 176
liposomes
amikacin, 1179
rifampin, 429
macrolides, 1614
rifampin, liposomal, 429
roxithromycin, 1614
Mycobacterium leprae
BACTEC 460, 2115
cephalothin, 657
chloramphenicol, 657
ciprofloxacin, 657
clarithromycin, 657, 2115
clindamycin, 657
clofazimine, 657, 2115
analogs, 657
cloxacillin, 657
D-cycloserine, 657
dapsone, 657, 2115
deoxyfructoserotonin
Schwann cell uptake, 866
erythromycin, 657
ethionamide, 657, 2115
gentamicin, 657
griseofulvin, 657
isoniazid, 657
kanamycin, 657
minocycline, 657, 2115
nalidixic acid, 657
ofloxacin, 2115
phenazines, tetramethylpiperidine substituted, 2004
phenolic glycolipid I synthesis, 657
polymyxin B, 657
rifabutin, 657
rifampin, 657, 2115
roxithromycin, 657
Schwann cell uptake
deoxyfructoserotonin, 866
4,4′-diaminodiphenyl sulfone, 866
rifampin, 866
serotonin derivative
Schwann cell uptake, 866
streptomycin, 657
susceptibility testing, 2115
tetracycline, 657
tetramethylpiperidine-substituted phenazines, 2004
trimethoprim, 657
Mycobacterium microti
isoniazid, 1255
mouse peritoneal macrophages, 1255
pyrazinamide, 1255
rifampin, 1255
streptomycin, 1255
Mycobacterium scrofulaceum
cadmium accumulation and transport, 350
Mycobacterium smegmatis
ethambutol
arabinogalactan synthesis, 1493

Mycobacterium spp.
AT-4140, 1167
ciprofloxacin, 1
minireview, 1
norfloxacin, 1
ofloxacin, 1
pefloxacin, 1
quinolones, 1
Mycobacterium tuberculosis
amikacin, 1298
capreomycin, 1298
clarithromycin, 591
difloxacin, 591
enoxacin, 591
fluoroquinolones, 591
Gen-Probe DNA Hybridization System, 1000
isoniazid, 1000
kanamycin, 1298
pefloxacin, 591
pyrazinamide, 1252
pyrazinoic acid, 1252
streptomycin, 1298
susceptibility testing, 1000
temafloxacin, 591
Mycoplasma hominis
pristinamycin, 2152
Mycoplasma spp.
AT-4140, 1167
Mycoplasmas
amifloxacin, 103
cinoxacin, 103
ciprofloxacin, 103
difloxacin, 103
enoxacin, 103
fleroxacin, 103
lomefloxacin, 103
nalidixic acid, 103
norfloxacin, 103
ofloxacin, 103
pefloxacin, 103
quinolones, 103
rosoxacin, 103
Myelopoiesis
ofloxacin, 122
pefloxacin, 122

Nafcillin
Staphylococcus spp.
surface colonizing, 813
Nalidixic acid
B. parapertussis, 968
C. pylori, 108
E. coli
DNA gyrase, 1816
P fimbriae, 684
E. gracilis, 1883
M. leprae, 657
mycoplasmas, 103
topoisomerase II, 1816
assays, 1697
Natamycin
Fusarium spp., 1647
Neisseria gonorrhoeae
amoxicillin-probenecid, 167
cefmetazole, 164
cefoxitin, 164
ceftriaxone, 164, 233
enoxacin, 233
FK482, 1795
lomefloxacin, 2049
ofloxacin, 167
penicillin, 164
penicillin G, 233
pristinamycin, 2152
QA-241, 1144
Ro 23-9424, 1072
spectinomycin, 164, 233
susceptibility testing, 233
tetracycline, 164
trospectomycin, 569
Neisseria meningitidis
amdinocillin, 1622
aztreonam, 1622
cefotaxime, 1622
ceftazidime, 1622
ceftizoxime, 1622
ceftriaxone, 1622
cefuroxime, 1622
chloramphenicol, 1622
ciprofloxacin, 1622
imipenem, 1622
mezlocillin, 1622
moxalactam, 1622
penicillin
diminished susceptibility, 1622
susceptibility, 1622
piperacillin, 1622
rifampin, 1622
sulfadiazine, 1622
tetracycline, 1622
Neisseria spp.
AM-1091, 1036
AT-4140, 1167
Ro 23-9424, 944
SM-7338, 215, 1009
Nephrotoxicity
amikacin, 973
amphotericin B
sodium status, 1222
cisplatin
fosfomycin protective effect, 513
piperacillin protective effect, 513
daptomycin, 1280
daptomycin-tobramycin, 1280
gentamicin
ticarcillin protective effect, role of sodium in, 928
predictors, 973
tobramycin, 1280
Neplanocin A
parainfluenza virus, 1291
reovirus, 1291
rotavirus, 1291
vaccinia virus, 1291
vesicular stomatitis virus, 1291
Netilmicin
Acinetobacter spp., 1617
combinations
azlocillin, 503
ceftriaxone, 767
ciprofloxacin, 87
E. coli, 767
endocarditis, 767
neutropenia, 503
neutropenic patients, 87
piperacillin, 87, 503
E. coli, 767
endocarditis, 767
P. shigelloides, 1609
Neutropenic patients
β-lactam combinations, 503
ceftazidime-azlocillin, 503
ceftazidime-piperacillin, 503
ciprofloxacin-netilmicin, 87
gentamicin
pharmacokinetics, 1890
hematological malignancy, 503
netilmicin-azlocillin, 503
netilmicin-piperacillin, 503
piperacillin-netilmicin, 87
Staphylococcus spp., 209
Streptococcus susceptibility, 580
nfxB
characterization, 283
Nifurtimox
antibacterial activities, 404
Nitrobenzylthioinosine 5'-monophosphate
schistosomiasis, 824
tubercidin host toxicity, prevention of, 824
Nitrofurantoin
C. pylori, 108
E. coli
hyperoxia, 1526
P. aeruginosa
hyperoxia, 1526
Nocardia spp.
tosufloxacin, 2140
norA
S. aureus
fluoroquinolone resistance, 1535
Norfloxacin
Acinetobacter spp., 1617
bioavailability
sucralfate, 99
bone marrow recipients
gram-negative organisms, 1709
gram-positive organisms, 1709
oral and intestinal microfloras, 1709
C. burnetii, 1052
C. pylori, 108, 256
comparative activity
trimethoprim-sulfamethoxazole, 1101
E. coli
P fimbriae, 684
postantibiotic effect, 1714
E. faecalis
postantibiotic effect, 1714
E. gracilis, 1883
Enterococcus spp., 71
gastritis, 256
gram-negative organisms, 1709
gram-positive organisms, 1709
high-performance liquid chromatography, 99
letter to the editor, 595
minireview, 1
Mycobacterium spp., 1
mycoplasmas, 103
nonulcerative dyspepsia, 256
P. aeruginosa
postantibiotic effect, 1714
P. shigelloides, 1609
S. aureus
postantibiotic effect, 1714
S. marcescens, 785
shigellosis, 1101
Staphylococcus spp., 209
theophylline elimination, 212
topoisomerase II assays, 1697
urinary tract infections, 1032
resistance, 595
Nosocomial infections
gram-negative bacteremia, 1855
Novobiocin
E. gracilis, 1883

Nuclear magnetic resonance spectroscopy
flucytosine
Aspergillus metabolism, 1939
Nucleic acid assay
tetM, 1813
Nucleoside analogs
combinations
human immunodeficiency virus type 1, 2083
phosphonoformate, 2083
fluorine substitutions
structure-activity relationships, 2083
Nystatin
S. cerevisiae
ergosterol specificity, 2092

Obese athletes
cefotiam pharmacokinetics, 1188
Ocular alpha interferon
safety and tolerance, 396
Ofloxacin
Acinetobacter spp., 1617
B. melitensis, 1409
C. burnetii, 621, 1052
cerebrospinal fluid penetration
meningitis, 933
ventriculitis, 933
combinations
oxacillin, 2037
Staphylococcus spp., 2037
comparative activity
amoxicillin-probenecid, 167
trimethoprim-sulfamethoxazole, 1308
concentrations in serum and cerebrospinal fluid, 1686
cystitis, 1308
E. coli, 1308
DNA gyrase, 1816
E. gracilis, 1883
fluorometric assay
uptake by human polymorphonuclear leukocytes, 653
gonorrhea, 167
high-pressure liquid chromatography, 1686
M. leprae, 2115
meningitis
cerebrospinal fluid penetration, 933
minireview, 1
Mycobacterium spp., 1
mycoplasmas, 103
myelopoiesis, 122
N. gonorrhoeae, 167
S. aureus resistance, 593
S. marcescens, 785
Staphylococcus spp., 209
topoisomerase II, 1816
ventriculitis
cerebrospinal fluid penetration, 933
S-Ofloxacin
B. fragilis, 1105
comparative activity
ofloxacin, 1105
Enterobacteriaceae, 1105
gram-positive organisms, 1105
P. aeruginosa, 1105
S. aureus, 1105
S. pyogenes, 1105
Open-heart surgery
ceftriaxone pharmacokinetics, 850
Oral bacteria
N,N'-dialkylpolymethylenediamines, 1636
Oropharyngeal flora
ciprofloxacin, 1645
Osteomyelitis
cefazolin, 1760
clindamycin, 1760
daptomycin, 689
S. aureus, 689, 1760
vancomycin, 689
Ototoxicity
aminoglycosides, 797
erythromycin, 791
minireviews, 791, 797
vancomycin, 791
Outer membrane
E. coli
sodium hexametaphosphate, 1741
minireview, 1831
P. aeruginosa
sodium hexametaphosphate, 1741
P. aeruginosa permeability
cephaloridine, 1201
imipenem, 1201
Pseudomonas spp.
sodium hexametaphosphate, 1741
Outer membrane proteins
A. salmonicida, 19
E. cloacae, 937
E. coli
multiply antibiotic resistant, 1318
P. aeruginosa, 124
Oxacillin
combinations
fleroxacin, 2037
ofloxacin, 2037
quinolone, 2037
Staphylococcus spp., 2037
temafloxacin, 2037
S. aureus
postantibiotic effect, 2155
Oxetanocin
human immunodeficiency virus, 773
Oxolinic acid
E. gracilis, 1883
topoisomerase II assays, 1697

Paracoccidioides brasiliensis
ajoene, 1641
cilofungin, 1391
Parainfluenza virus
3-deazaneplanocin A, 1291
DHCA, 1291
DHCDA, 1291
9-(*trans*-2',*trans*-3'-dihydroxycyclopent-4'-enyl)adenine, 1291
9-(*trans*-2',*trans*-3'-dihydroxycyclopent-4'-enyl)-3-deazaadenine, 1291
neplanocin A, 1291
Paralysis
cephalosporin penetration of soft tissue, 1326
Paraxanthine
disposition
ciprofloxacin, 474
Paromomycin
G. lamblia, 484
Pasteurella multocida
cefaclor, 2142
cefadroxil, 2142
cefcanel, 2142
cefuroxime, 2142
cephalexin, 2142
kanamycin resistance, 670
R plasmids, 670
streptomycin resistance, 670
sulfonamide resistance, 670
tetracycline resistance, 670
Pediococcus spp.
daptomycin, 1383
teicoplanin, 1477
vancomycin, 1477
derivatives, 1477
Pefloxacin
bone marrow recipients
gram-negative organisms, 1709
gram-positive organisms, 1709
oral and intestinal microfloras, 1709
bronchial secretion concentrations, 391
C. burnetii, 621, 1052
C. pylori, 108
comparative activity
ceftazidime, 1362
E. cloacae
resistance selection, 937
Enterobacteriaceae, 1362
gram-negative organisms, 1709
infections, 1362
gram-positive organisms, 1709
M. tuberculosis, 591
minireview, 1
Mycobacterium spp., 1
mycoplasmas, 103
myelopoiesis, 122
P. aeruginosa, 1362
peritonitis, 937
Staphylococcus spp., 209
Streptococcus spp., 580
Penciclovir
oral prodrug, 1765
pharmacokinetics, 1765
Penicillin
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
combinations
E. faecalis, 608
gentamicin, 608
postantibiotic effect, 608
killing mechanism
absence of lysis, 1680
N. gonorrhoeae, 164
N. meningitidis
diminished susceptibility, 1622
susceptibility, 1622
S. pneumoniae, 1111
Streptococcus spp., 580
Streptococcus spp., group A
mechanism of killing, 1680
Penicillin G
combinations
clavulanic acid, 331
S. aureus, 331
sulbactam, 331
N. gonorrhoeae, 233
Penicillin-binding proteins
CP-65,207 affinity, 1160
E. coli, 2101
C. freundii β-lactamase induction by 6-aminopenicillanic acid, 1116
H. ducreyi, 983
H. influenzae, 1878
S. aureus, 120
methicillin resistance, 1869

modified capacity, 1869
normal proteins with modified capacity, 1869
S. muenchen, 1113
Pentatroxane
T. gondii, 1748
Peptidoglycan synthesis
E. coli
β-lactamases, 2101
β-lactams, 2101
Peptococcus spp.
CP-65,207, 1160
Peritoneal dialysis fluids
gentamicin, 1553
gentamicin-cefazolin, 1553
imipenem, 1553
Peritoneal macrophages
isoniazid, 1255
M. microti, 1255
pyrazinamide, 1255
rifampin, 1255
streptomycin, 1255
Peritonitis
E. cloacae, 937
pefloxacin, 937
Pharmacokinetics
amikacin, 973
aplastic anemia, 1406
hematologic malignancies, 1406
aminoglycosides, 448
amopyroquin, 316
amoxicillin
aluminum magnesium hydroxide, 1901
pirenzepine, 1901
ranitidine, 1901
amoxicillin-clavulanic acid
aluminum magnesium hydroxide, 1901
pirenzepine, 1901
ranitidine, 1901
amphotericin B
children, 1989
ampicillin-sulbactam
renal insufficiency, 1470
azidothymidine, 810
azlocillin
two dosages, 710
BMY 28232, 489
BMY 40062, 906
BRL 39123, 1765
BRL 42810, 1765
carbovir, 171
cefazolin
surgical wounds, 700
cefetamet
age, 291
renal insufficiency, 1952
cefetamet pivoxil
age, 291
ascending doses, 957
renal insufficiency, 1952
cefixime
antacid, aluminum-magnesium, 1994
cefmetazole, 356, 508
probenecid pretreatment, 356
skin window technique, 924
cefonicid
age, 142
renal function, 142
cefotiam
obese athletes, 1188
cefoxitin, 356
ceftazidime, 693
ceftriaxone
open-heart surgery, 850
cephalexin
aluminum magnesium hydroxide, 1901
pirenzepine, 1901
ranitidine, 1901
ciprofloxacin, 1645, 1841
age, 1927
caffeine, 474
nasogastric tube administration, 1118
clarithromycin, 751
clindamycin phosphate, 618
diffusion coefficients, 1286
doxycycline
aluminum magnesium hydroxide, 1901
antacids, 434
pirenzepine, 1901
ranitidine, 1901
enoxacin
antacids, 615
ranitidine, 615
erythromycin, 751
famciclovir, 1765
fleroxacin
renal function, 373
fluconazole, 467, 714, 963
fluoroquinolones
minireview, 1655
foscarnet
cytomegalovirus retinitis, 742
human immunodeficiency virus, 1023
gentamicin
extracorporeal membrane oxygenation, 817
intracortical accumulation, effect of age on, 2006
neutropenic patients, 1890
surgical wounds, 700
(*R,S*)-9[4-hydroxy-2-(hydroxymethyl)butyl]guanine, 110
9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, 1765
imipenem
colorectal surgery, 204
macrolides
minireview, 1419
mezlocillin, 839
penciclovir, 1765
rifabutin, 1237
SCH39304, 1735, 1932
teicoplanin, 82
renal insufficiency, 2012
theophylline
lomefloxacin, 1006
ticarcillin, 693
ticarcillin-clavulanic acid, 693
vancomycin
endotoxemic rats, 1575
Phenazines
tetramethylpiperidine substituted
M. leprae, 2004
structure-activity relationships, 2004
2-Phenyl-1,2-benzoisoselenazol-3(2*H*)-one
Enterobacteriaceae, 1388
S. aureus, 1388
Phosphanilic acid
dihydropteroate synthase, 1936
E. coli, 1936
P. aeruginosa, 1936
Phosphonoacetic acid
herpes simplex virus
ribonucleotide reductase mutants, 1395
type 2, 635
Phosphonoformate
combinations
3′-azido-3′-deoxythymidine, 663
cytomegalovirus, 663
human immunodeficiency virus type 1, 663, 2083
nucleoside analogs, 2083
zidovudine, 663
9-(2-Phosphonylmethoxyethyl)adenine
combinations
3′-azido-3′-deoxythymidine, 1482
AZT, 1482
human immunodeficiency virus type 1, 1482
comparative activity
acyclovir and azidothymidine, 1864
herpes simplex virus
type 1, 185, 1864
type 2, 185
human immunodeficiency virus
type 1, 1482
murine acquired immunodeficiency disease, 1864
vaccinia virus, 185
9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine
herpes simplex virus
type 1, 185
type 2, 185
vaccinia virus, 185
Pichia anomala
anti-*Candida* toxin, 48
Pipemidic acid
S. marcescens, 785
Piperacillin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
B. parapertussis, 968
cisplatin nephrotoxicity
protective effect, 513
combinations
ceftazidime, 503
clavulanic acid, 1964
gentamicin, 1500
netilmicin, 87, 503
neutropenic patients, 87, 503
P. aeruginosa, 1500
sulbactam, 1964
tazobactam, 1268, 1964
comparative activity
clavulanic acid, piperacillin-tazobactam, tazobactam, ticarcillin, ticarcillin-clavulanate, 1268
E. coli, 382
N. meningitidis, 1622
Streptococcus spp., 580
Piperacillin-netilmicin
comparative activity
ciprofloxacin-netilmicin, 87
fever in neutropenic patients, 87
Piperacillin-tazobactam
comparative activity
clavulanic acid, piperacillin, tazobactam, ticarcillin, and ticarcillin-clavulanate, 1268
Pirenzepine
amoxicillin bioavailability, 1901
amoxicillin-clavulanic acid bioavailability, 1901
cephalexin bioavailability, 1901
doxycycline bioavailability, 1901

Piritetrate
C. neoformans, 2118
Candida spp., 2118
comparative activity
clotrimazole, tolciclate, and tolnaftate, 2118
fungi, 2118
T. mentagrophytes, 2118
Piritrexim
combinations
sulfadiazine, 1753
T. gondii, 1753
T. gondii, 1753
Plasmids
B. catarrhalis, 1845
E. coli, 595, 757
β-lactamase, 1958
K. pneumoniae, 757, 951, 1915
letter to the editor, 595
M. nonliquefaciens, 1845
resistance
A. pleuropneumoniae, 235
A. viridans, 529
E. coli, 535, 2042
E. faecium, 10
gnotobiotic animal model, 535
H. ducreyi, 1611, 1627
P. multocida, 670
S. haemolyticus, 460
selection, 535
Staphylococcus spp., 1335
Plasmodium falciparum
amopyroquin, 316
5-fluoroorotic acid, 1090
Plasmodium spp.
acridone alkaloids, 6
atalaphillinine, 6
Plasmodium yoelii
acridone alkaloids, 6
atalaphillinine, 6
Plesiomonas shigelloides
cephalosporins, 1609
ciprofloxacin, 1609
diarrhea, 1609
netilmicin, 1609
norfloxacin, 1609
trimethoprim, 1609
PMEA
combinations
3′-azido-3′-deoxythymidine, 1482
AZT, 1482
human immunodeficiency virus type 1, 1482
comparative activity
acyclovir and azidothymidine, 1864
herpes simplex virus
type 1, 185, 1864
type 2, 185
human immunodeficiency virus
type 1, 1482
murine acquired immunodeficiency disease, 1864
vaccinia virus, 185
PMEDAP
herpes simplex virus
type 1, 185
type 2, 185
vaccinia virus, 185
Poly(ICLC)
arboviruses, 2126
Banzi virus, 2126
combinations
antiserum, 2126
Semliki Forest virus, 2126
Polyisohexylcyanoacrylate nanoparticles
ampicillin, bound
salmonellosis, 1540
Polymyxin B
Acinetobacter spp., 1617
comparative activity
polymyxin B nonapeptide, 1428
M. leprae, 657
P. aeruginosa, resistant
fatty acid alterations, 1724
lipopolysaccharide binding, 1724
Polymyxin B nonapeptide
antiendotoxin activity, 1428
comparative activity
polymyxin B, 1428
purification, 1428
toxicity, 1428
Porins
C. coli, 297
C. jejuni, 297
Postantibiotic effect
amikacin, 1714
daptomycin
E. faecalis, 1198
S. aureus, 1198
electronic counting, 2155
imipenem, 1714
norfloxacin, 1714
penicillin-gentamicin, 608
Pristinamycin
C. trachomatis, 2152
comparative activity
ampicillin, ciprofloxacin, erythromycin, and tetracycline, 2152
G. vaginalis, 2152
M. hominis, 2152
Mediterranean spotted fever, 2146
N. gonorrhoeae, 2152
R. conorii, 2146
R. rickettsii, 2146
Rocky Mountain spotted fever, 2146
U. urealyticum, 2152
Probenecid
combinations
amoxicillin, 167, 801
gonococcal infections, 801
gonorrhea, 167
N. gonorrhoeae, 167
Propionibacterium acnes
benzoyl peroxide, 326
lipids, 326
Prostatitis
fluoroquinolones
minireview, 1655
Proteus mirabilis
FK482, 1795
Proteus spp.
piperacillin-tazobactam, 1964
SM7338, 1232
Proteus vulgaris
BMY-28232, 489
FK482, 1795
SM-7338, 1009
Providencia spp.
FK482, 1795
Pseudomonas aeruginosa
AAC(6′)-II gene, 2052
6′-*N*-acetyltransferase gene, 2052
amikacin
postantibiotic effect, 1714
aminoglycoside-modifying enzymes, 2052
aminoglycosides, 1368
6-aminopenicillanic acid
β-lactamase induction, 1435
cell surface changes, 1435
antibiotic combination susceptibility, 1368
AT-4140, 1980
aztreonam, 526
β-lactamases, 498
6-aminopenicillanic acid induction, 1435
biological fluids, 776
production and induction, 776
SM7338, 1232
β-lactams, 1368
BMY 40062, 906
cancer patients
risk of colonization with antibiotic treatment, 1400
cefazolin-gentamicin
peritoneal dialysis fluids, 1553
cefepime, 498
cefoperazone, 35
ceftazidime, 41, 526, 1362
ceftizoxime, 35
ceftriaxone, 35
cell surface changes
6-aminopenicillanic acid, 1435
cephalosporin resistance, 498
ciprofloxacin, 41, 526, 1368
accumulation, 1921
DNA synthesis, 1457
mutants, selected, 124
uptake, 1457
CP-65,207, 1160
cross resistance, 1368
cystic fibrosis, 526
dactimicin, 1998
dihydropteroate synthase, 1936
enoxacin, 1804
exoenzymes, 41
gentamicin, 1804
hyperoxia, 1526
killing curve analysis, 1500
peritoneal dialysis fluids, 1553
serum bactericidal rate, 1500
gentamicin-cefazolin
peritoneal dialysis fluids, 1553
gentamicin-piperacillin
killing curve analysis, 1500
serum bactericidal rate, 1500
hyperoxia and susceptibility, 1526
imipenem
peritoneal dialysis fluids, 1553
postantibiotic effect, 1714
imipenem resistance
outer membrane permeability, 1201
in vitro chemostat system
antibiotic interaction, 1824
interleukin-1α, 1804
interleukin-1α–ceftazidime, 1804
interleukin-1α–enoxacin, 1804
interleukin-1α–gentamicin, 1804
interleukin-1α–immunoglobulin, 1804
ME1228, 1260
moxalactam, 35
mucoid and nonmucoid PAO1 derivatives
tobramycin, 1207
nitrofurantoin
hyperoxia, 1526
norfloxacin
postantibiotic effect, 1714

S-ofloxacin, 1105
outer membrane permeability
cephaloridine, 1201
imipenem, 1201
outer membrane proteins, 124
pefloxacin, 1362
phosphanilic acid, 1936
polymyxin B resistant
fatty acid alterations, 1724
polymyxin B binding by lipopolysaccharides, 1724
QA-241, 1144
quinolone resistance, 624
risk of colonization
antibiotic treatment, 1400
cancer patients, 1400
Ro 23-9424, 944
SM-7338, 1009, 1232
sodium hexametaphosphate
outer membrane disruption, 1741
sulfamethoxazole
hyperoxia, 1526
susceptibility patterns, changing, 526
tobramycin, 41, 1207
hyperoxia, 1526
trimethoprim
hyperoxia, 1526
Pseudomonas cepacia
chloramphenicol resistance, 136
dihydrofolate reductase, 1247
sulbactam, 583
trimethoprim
resistance, 1247
Pseudomonas spp.
AM-1091, 1036
AT-4140, 1167
BO-1341, 1423
FK482, 1795
Ro 23-9424, 1072
SM-7338, 215, 562
sodium hexametaphosphate
outer membrane disruption, 1741
Purine 2′,3′-dideoxynucleosides
comparative activity
duck hepadnavirus, 336
Pyrazinamide
comparative activity
pyrazinoic acid, 1252
M. microti, 1255
mouse peritoneal macrophages, 1255
M. tuberculosis, 1252
Pyrazinoic acid
comparative activity
pyrazinamide, 1252
M. tuberculosis, 1252
Pyrimethamine
combinations
sulfadiazine, 1753
sulfisoxazole, 1753
T. gondii, 30, 1753
zidovudine, 30
T. gondii, 30, 1753
Pyrimidine 2′,3′-dideoxynucleosides
comparative activity
duck hepadnavirus, 336
2-Pyrimidinone 2′-deoxyribonucleoside analogs, 5-substituted
herpes simplex virus
type 1, 340
type 2, 340
PZ51
Enterobacteriaceae, 1388
S. aureus, 1388
QA-241
B. fragilis, 1144
B. pertussis, 1144
C. freundii, 1144
comparative activity
ciprofloxacin, enoxacin, norfloxacin, and ofloxacin, 1144
E. coli, 1144
E. faecalis, 1144
gram-negative organisms, 1144
gram-positive organisms, 1144
H. influenzae, 1144
K. pneumoniae, 1144
N. gonorrhoeae, 1144
P. aeruginosa, 1144
S. marcescens, 1144
Staphylococcus spp., 1144
Streptococcus spp., 1144
X. maltophilia, 1144
Quinolones
combinations
oxacillin, 2037
Staphylococcus spp., 2037
DNA gyrase A gene, 886
E. coli resistance, 283, 886
gyrA and *gyrB* mutations, 254
E. coli, tolerant, 705
E. gracilis
chloroplast elimination, 1883
fluorometric assay, 27
γ-aminobutyric acid receptors, 1704
minireview, 1
Mycobacterium spp., 1
mycoplasmas, 103
P. aeruginosa resistance, 624
S. aureus resistance, 593
S. marcescens resistance, 785
structure-epileptogenicity relationship, 1704
topoisomerase II assays, 1697

R837
herpes simplex virus
type 2, 1511
R61837
colds, 522
rhinovirus, 522
Radioimmunoassays
ribavirin
comparative study, 311
Ranitidine
amoxicillin bioavailability, 1901
amoxicillin-clavulanic acid bioavailability, 1901
cephalexin bioavailability, 1901
doxycycline bioavailability, 1901
enoxacin pharmacokinetics, 615
Reovirus
3-deazaneplanocin A, 1291
DHCA, 1291
DHCDA, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)adenine, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-3-deazaadenine, 1291
neplanocin A, 1291
Resistance
minireview, 1831
Respiratory infections
zinc gluconate, 646
Retinitis
cytomegalovirus
acquired immunodeficiency syndrome, 736
foscarnet, 736
Reuterin
chemical characterization, 674
Reverse transcriptases
feline immunodeficiency virus, 915
human immunodeficiency virus type 1, 115
3′-azido-2′,3′-dideoxyuridine-5′-triphosphate, 1729
azidothymidine triphosphate, 2109
simian immunodeficiency virus
3′-azido-2′,3′-dideoxyuridine-5′-triphosphate, 1729
Rhinovirus
alpha 2b interferon
postexposure prophylaxis, 387
R61837, 522
WIN 54954, 2069
zinc gluconate, 646
Ribavirin
high-performance liquid chromatography, 311
La Crosse virus
mechanism of inhibition, 2009
phosphorylated
inhibition kinetics, 1668
vesicular stomatitis virus, 1668
radioimmunoassay, 311
Rickettsia conorii
pristinamycin, 2146
roxithromycin, 2146
Rickettsia rickettsii
pristinamycin, 2146
roxithromycin, 2146
Rifabutin
C. trachomatis, 1393
high-pressure liquid chromatography, 1237
human immunodeficiency virus, 1237
M. leprae, 657
pharmacokinetics, 1237
Rifampin
B. avium, 771
B. bronchiseptica, 771
B. melitensis, 1409
C. burnetii, 1052
C. trachomatis
resistance, 1393
ciprofloxacin elimination, 589
combinations
ciprofloxacin, 181, 1184
clindamycin, 245
endocarditis, 1184
fleroxacin, 2037
S. aureus, 181, 1184
Staphylococcus spp., 245, 2037
comparative activity
ciprofloxacin, ciprofloxacin-rifampin, and vancomycin, 1184
endocarditis, 1184
liposomal
M. avium complex, 429
M. leprae, 657, 2115
M. microti, 1255
mouse peritoneal macrophages, 1255
N. meningitidis, 1622
S. aureus, 1184
Staphylococcus spp., 245
Rimantadine
disposition
cimetidine, effect of, 820

Ro 15-0216
T. b. brucei, 881
T. b. evansi, 881
Ro 23-9424
Acinetobacter spp., 1072
B. catarrhalis, 944, 1072
Bacillus spp., 944
C. jeikeium, 944
comparative activity
amikacin, cefotaxime, ceftazidime, ciprofloxacin, fleroxacin, and imipenem, 1072
cefotaxime, desacetylcefotaxime, desacetylcefotaxime-fleroxacin, and fleroxacin, 944
Enterobacteriaceae, 944, 1072
Enterococcus spp., 944, 1072
H. influenzae, 944, 1072
L. monocytogenes, 944
mechanism of action, 1067
N. gonorrhoeae, 1072
Neisseria spp., 944
P. aeruginosa, 944
Pseudomonas spp., 1072
Staphylococcus spp., 944
Rocky Mountain spotted fever
pristinamycin, 2146
roxithromycin, 2146
Rokitamycin
B. fragilis, accumulation by, 242
hydrophobicity, 242
Rosoxacin
mycoplasmas, 103
Rotavirus
3-deazaneplanocin A, 1291
DHCA, 1291
DHCDA, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)adenine, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-3-deazaadenine, 1291
neplanocin A, 1291
Roxithromycin
C. pneumoniae, 1634
C. pylori, 1650
M. avium complex, 1614
M. leprae, 657
Mediterranean spotted fever, 2146
R. conorii, 2146
R. rickettsii, 2146
Rocky Mountain spotted fever, 2146

Saccharomyces cerevisiae
amphotericin B
ergosterol specificity, 2092
chromatin
bleomycin, 1592
cleavage and degradation, 1592
nystatin
ergosterol specificity, 2092
polyclonal antibodies
ergosterol specificity, 2092
nystatin, 2092
sterol immunolabeling, 2092
Salicylates
E. coli
cephalosporin uptake, 412
Salmonella dublin
3′-azido-3′-deoxythymidine, 479
zidovudine, 479
Salmonella muenchen
ampicillin resistance, 1113
penicillin-binding proteins, 1113
Salmonella spp.
dactimicin, 1998
FK482, 1795
lomefloxacin, 1385
piperacillin-tazobactam, 1964
temafloxacin, 1385
Salmonella typhimurium
amifloxacin, 1837
aminoglycosides
tet expression, 1549
tet
aminoglycoside uptake, 1549
Salmonellosis
ampicillin, 1540
polyisohexylcyanoacrylate nanoparticle bound, 1540
San Angelo virus
7-thia-8-oxoguanosine, 1487
Saperconazole
aspergillosis
normal and immunocompromised animals, 2063
Aspergillus spp., 2063
comparative activity
amphotericin B, 2063
SCH39304
C. albicans, 1095
endocarditis, 1735
endophthalmitis, 1735
C. neoformans
meningitis, 1735
candidiasis, 1735
comparative activity
amphotericin B and fluconazole, 1242
fluconazole, 1095, 1735
cryptococcosis, 1735
endocarditis
C. albicans, 1735
endophthalmitis
C. albicans, 1735
granulocytopenic and nongranulocytopenic rabbits, 1932
meningitis
C. neoformans, 1735
crytococcal, 1242
murine cryptococcosis, 1242
pharmacokinetics, 1735, 1932
susceptibility testing, 1095
tissue penetration, 1932
yeasts, 1095
Schistosoma mansoni
artemether
in vitro, in vivo, and histopathologic effects, 1557
Schistosomiasis
tubercidin host toxicity, prevention of nitrobenzylthioinosine 5′-monophosphate, 824
Semliki Forest virus
antiserum, 2126
poly(ICLC), 2126
poly(ICLC)-antiserum, 2126
7-thia-8-oxoguanosine, 1487
Septicemia
Staphylococcus spp., 209
Serotonin
derivative
M. leprae, 866
Schwann cell uptake, 866
Serratia marcescens
AT-4140, 1980
CP-65,207, 1160
dactimicin, 1998
norfloxacin, 785
ofloxacin, 785
pipemidic acid, 785
QA-241, 1144
quinolone resistance, 785
T-3262, 785
Serratia spp.
FK482, 1795
Shigella spp.
FK482, 1795
lomefloxacin, 1385
piperacillin-tazobactam, 1964
temafloxacin, 1385
Shigellosis
norfloxacin, 1101
trimethoprim-sulfamethoxazole, 1101
Shunt infections
cefuroxime
ventricular fluid concentrations, 1108
SHV-3
structure, 2096
SHV-5
description, 951
Simian acquired immunodeficiency syndrome
2′,3′-dideoxycytidine, 1908
Simian immunodeficiency virus
3′-azido-2′,3′-dideoxyuridine-5′-triphosphate, 1729
reverse transcriptase, 1729
Simian retrovirus type 2
2′,3′-dideoxycytidine, 1908
Sinefungin
T. b. brucei, 881
T. b. evansi, 881
SKF104662
C. difficile, 560
comparative activity
clindamycin, daptomycin, teicoplanin, and vancomycin, 965
daptomycin, teicoplanin, and vancomycin, 560
Enterococcus spp., 560
gram-positive bacteria, 560, 965
S. epidermidis, 560
S. haemolyticus, 560
Staphylococcus spp., 560
Streptococcus spp., 560
Skin infections
ciprofloxacin, 181
ciprofloxacin-rifampin, 181
clotrimazole, 970
fenticonazole, 970
metronidazole, 970
miconazole, 970
rifampin-ciprofloxacin, 181
S. aureus, 181
tetracycline, 970
Skin window technique
cefmetazole pharmacokinetics, 924
Slime
Staphylococcus spp., 209
SM-7338
Acinetobacter spp., 562
Bacteroides spp., 215, 1009
β-lactamases, 1009
Branhamella spp., 215, 1009
Clostridium spp., 215
comparative activity
cefotaxime, ceftazidime, gentamicin, imipenem, and piperacillin, 215, 1009

cefotaxime, ceftazidime, and imipenem, 562
ciprofloxacin and imipenem, 1232
Enterobacteriaceae, 215, 562, 1009, 1232
Enterococcus spp., 562
H. influenzae, 215
Haemophilus spp., 1009
M. morganii, 1232
Morganella spp., 1009
Neisseria spp., 215, 1009
P. aeruginosa, 1009, 1232
β-lactamase, 1232
P. vulgaris, 1009
Proteus spp., 1232
Pseudomonas spp., 215, 562
S. aureus, 215
Staphylococcus spp., 562, 1009
Streptococcus spp., 215, 1009
X. maltophilia, 215, 562
Soap
human immunodeficiency virus type 1, 2034
Sodium
ticarcillin protective effect
gentamicin nephrotoxicity, 928
Sodium hexametaphosphate
E. coli, 1741
outer membrane disruption, 1741
P. aeruginosa, 1741
Pseudomonas spp., 1741
Sodium hydroxide
aminoglycoside extraction, 448
Sodium status
amphotericin B nephrotoxicity, 1222
Soft tissue infections
ciprofloxacin, 181
ciprofloxacin-rifampin, 181
paralysis
cephalosporin penetration, 1326
rifampin-ciprofloxacin, 181
S. aureus, 181
Spectinomycin
N. gonorrhoeae, 164, 233
Spiramycin
A. actinomycetemcomitans, 2016
Bacteroides spp., 2016
Lactobacillus spp., 2016
S. mutans, 2016
T. denticola, 2016
Staphylococcus aureus
amikacin
postantibiotic effect, 1714
amoxicillin
N-formyl peptide conjugate, 1516
ampicillin
N-formyl peptide conjugates, 1516
AT-4140, 1980
β-lactamases, 331
BMY 28232, 489
BMY 40062, 906
BO-1341, 1423
burn wounds, 1358
catheters
dicloxacillin coating, 1174
cefazolin, 1760
cefazolin-clavulanic acid, 331
cefazolin-sulbactam, 331
cefmetazole-clavulanic acid, 331
cefmetazole-sulbactam, 331
cefoperazone, 35
cefotaxime-clavulanic acid, 331
cefotaxime-sulbactam, 331
cefotiam-clavulanic acid, 331
cefotiam-sulbactam, 331
cefpirome-clavulanic acid, 331
cefpirome-sulbactam, 331
ceftizoxime, 35
ceftriaxone, 35
ciprofloxacin, 128, 181, 1184
resistance, 593
ciprofloxacin-rifampin, 181, 1184
clindamycin, 1760
cloxacillin, 980
colonization, 181
cyclophosphamide, 980
dactimicin, 1998
daptomycin, 689, 1280
postantibiotic effect, 1198
dicloxacillin
catheter coating, 1174
elfamycins
elongation factor Tu, 322
protein synthesis, 322
endocarditis, 519, 1184
erythromycin, 980
etoposide, 980
FCE 22101, 120
FK482, 1795
fleroxacin, 519
flomoxef-clavulanic acid, 331
flomoxef-sulbactam, 331
fluoroquinolone resistance
norA gene, 1535
granulocytopenia, 980
imipenem
postantibiotic effect, 1714
macrolide-lincosamide-streptogramin B resistance, 541
ME1228, 1260
methicillin resistance
low level, 424
normal penicillin-binding proteins with modified capacity, 1869
methicillin-clavulanic acid, 331
methicillin-sulbactam, 331
monocytopenia, 980
moxalactam, 35
moxalactam-clavulanic acid, 331
moxalactam-sulbactam, 331
mupirocin, 1358
transport, 156
norA gene
fluoroquinolone resistance, 1535
norfloxacin
postantibiotic effect, 1714
ofloxacin
resistance, 593
S-ofloxacin, 1105
osteomyelitis, 689, 1760
oxacillin
postantibiotic effect, 2155
penicillin G-clavulanic acid, 331
penicillin G-sulbactam, 331
penicillin-binding proteins, 120
2-phenyl-1,2-benzoisoselenazol-3(2*H*)-one, 1388
PZ51, 1388
quinolone resistance, 593
rifampin, 1184
rifampin-ciprofloxacin, 181, 1184
skin infections, 181
SM-7338, 215
soft tissue infections, 181
Tn*554* insertion, 541
vancomycin, 689, 1184, 1280
Staphylococcus epidermidis
daptomycin, 585
gentamicin
resistance, 1335
macrolide-lincosamide-streptogramin B resistance, 541
SKF104662, 560
teicoplanin, 585
Tn*554* insertion, 541
Tn*4031*, 1335
Staphylococcus haemolyticus
daptomycin, 585
DNA probes, 460
erythromycin resistance, 460
gentamicin resistance, 460
methicillin resistance, 460
R plasmids, 460
SKF104662, 560
teicoplanin, 585
resistance, 460
trimethoprim resistance, 460
vancomycin resistance, 460
Staphylococcus spp.
AM-1091, 1036
amifloxacin, 762
metabolites, 762
aminoglycoside-modifying enzymes, 1335
AT-4140, 1167
BMY 40062, 906
cefazolin-gentamicin
peritoneal dialysis fluid, 1553
cephalosporins, 407
ciprofloxacin, 209
clindamycin, 245
clindamycin-rifampin, 245
CP-65,207, 1160
dactimicin, 1998
daptomycin, 813, 1522, 1783
daptomycin-amikacin, 1783
endocarditis, 871, 1329, 1522
enoxacin, 877
gentamicin, 209, 813
peritoneal dialysis fluid, 1553
resistance, 1335
gentamicin-cefazolin
peritoneal dialysis fluid, 1553
gentamicin-fleroxacin, 2037
imipenem, 209
peritoneal dialysis fluid, 1553
KB-5246, 1896
ME1228, 1260
methicillin resistance
detection, 995
genetics, 991
mechanisms, 991
minireviews, 991, 995
restriction map, 1624
treatment of infections, 995
minireview, 407
nafcillin, 813
neutropenic patients, 209
norfloxacin, 209
ofloxacin, 209
oxacillin-fleroxacin, 2037
oxacillin-ofloxacin, 2037
oxacillin-quinolone, 2037
oxacillin-temafloxacin, 2037
pefloxacin, 209
piperacillin-tazobactam, 1964
plasmids, 1335
QA-241, 1144
quinolone-oxacillin, 2037

resistance, 813
rifampin, 245
rifampin-clindamycin, 245
rifampin-fleroxacin, 2037
Ro 23-9424, 944
septicemia, 209
SKF104662, 560
slime production, 209
SM-7338, 562, 1009
surface colonizing, 813
teicoplanin, 871, 1329, 2019
tobramycin resistance
restriction map, 1624
urinary tract infection, 877
vancomycin, 813, 2019
vancomycin-fleroxacin, 2037
Streptococcus faecalis subsp. *liquefaciens*
antibiotic AS-48
amino acid composition, 437
purification, 437
Streptococcus mutans
spiramycin, 2016
Streptococcus pneumoniae
AM-1091, 1036
ampicillin, 418
KB-5246, 1896
ME1228, 1260
penicillin, 1111
teicoplanin, 2019
vancomycin, 2019
Streptococcus pyogenes
clarithromycin
analogs, 78
erythromycin
analogs, 78
KB-5246, 1896
macrolide resistance, 78
S-ofloxacin, 1105
Streptococcus spp.
amikacin, 580
ampicillin, 580
AT-4140, 1167
BMY 40062, 906
BO-1341, 1423
cefamandole, 580
cefotaxime, 580
ceftazidime, 580
CP-65,207, 1160
daptomycin, 1522
N,N'-dialkylpolymethylenediamines, 1636
endocarditis, 871, 1522
FK482, 1795
gentamicin, 580
group A
penicillin, 1680
imipenem, 580
ME1228, 1260
pefloxacin, 580
penicillin, 580
piperacillin, 580
QA-241, 1144
septicemia in neutropenic patients, 580
SKF104662, 560
SM-7338, 215, 1009
streptomycin, 580
teicoplanin, 580, 871
vancomycin, 580
Streptomyces griseus
streptomycin-Park nucleotide complex, 58
Streptomyces vendargensis
erythromycin A glycosylation, 2089
Streptomycin
A. pleuropneumoniae resistance, 235
A. viridans resistance, 529
B. melitensis, 1409
B. parapertussis, 968
comparative activity
amikacin, capreomycin, and kanamycin, 1298
M. avium, 1298
M. leprae, 657
M. microti, 1255
mouse peritoneal macrophages, 1255
M. tuberculosis, 1298
P. multocida
resistance, 670
Streptococcus spp., 580
Streptomycin-Park nucleotide complex
S. griseus, 58
Sucralfate
norfloxacin bioavailability, 99
Sulbactam
Acinetobacter spp., 1617
combinations
ampicillin, 1470
pharmacokinetics, 1470
P. cepacia, 583
Sulfadiazine
combinations
piritrexim, 1753
pyrimethamine, 1753
T. gondii, 1753
trimetrexate-glycuronate, 1753
N. meningitidis, 1622
T. gondii, 1753
Sulfamethoxazole
B. parapertussis, 968
C. pneumoniae, 1634
E. coli
hyperoxia, 1526
P. aeruginosa
hyperoxia, 1526
T. gondii, 1753
Sulfathiazole
E. coli
resistance, 2042
Sulfisoxazole
combinations
pyrimethamine, 1753
T. gondii, 1753
T. gondii, 1753
Sulfonamides
A. pleuropneumoniae resistance, 235
combinations
dihydrofolate reductase inhibitors, 1753
T. gondii, 1753
E. coli
resistance, 2042
P. multocida
resistance, 670
T. gondii, 1753
Suramin
human immunodeficiency virus type 1 reverse transcriptases, 115
Surgical wounds
cefazolin penetration, 700
gentamicin penetration, 700
Susceptibility testing
B. fragilis group, 394
BACTEC 460
M. leprae, 2115
cilofungin
medium, 731
pH, 731
daptomycin, 585
letter to the editor, 1652
Staphylococcus spp., 1652
E. faecalis
vancomycin resistance, 1588
M. leprae
BACTEC 460, 2115
M. tuberculosis, 1000
N. gonorrhoeae, 233
SCH39304, 1095
teicoplanin, 585
trospectomycin, 569
Syphilis
cefmetazole, 1465
penicillin, 1465

T-3262
E. coli
DNA gyrase, 1816
S. marcescens, 785
topoisomerase II, 1816
Taxol
T. b. brucei, 881
T. b. evansi, 881
Tazobactam
combinations
B. fragilis group, 1964
E. coli, 1964
K. pneumoniae, 1964
Morganella spp., 1964
piperacillin, 1268, 1964
Proteus spp., 1964
Salmonella spp., 1964
Shigella spp., 1964
Staphylococcus spp., 1964
comparative activity
clavulanic acid and sulbactam, 1964
clavulanic acid, piperacillin, piperacillin-tazobactam, ticarcillin, and ticarcillin-clavulanate, 1268
Teicoplanin
C. difficile-associated disease, 1125
catheter-related infections, 1193
combinations
aminoglycoside, 871
gram-positive cocci, 871
comparative activity
ciprofloxacin, clindamycin, gentamicin, penicillin, trimethoprim-sulfamethoxazole, and vancomycin, 2019
daptomycin, fusidic acid, rifampin, and vancomycin, 585
vancomycin, 1125, 1193
E. faecalis, 251, 871, 1588
E. faecium resistance, transferable, 10
endocarditis, 871, 1329
Enterococcus spp., 1329, 1477, 2019
high-performance liquid chromatography, 1791
Lactobacillus spp., 1477
Leuconostoc sp., 1477
M. sedentarius, 871
metabolism in rats, 1791
Pediococcus spp., 1477
pharmacokinetics, 82
renal insufficiency, 2012
S. epidermidis, 585
S. haemolyticus, 585
resistance, 460
S. pneumoniae, 2019

Staphylococcus spp., 871, 1329, 2019
Streptococcus spp., 580, 871
susceptibility testing, 585
TEM
multiplicity, 1915
TEM-4
description, 1958
TEM-10
description, 1451
Temafloxacin
C. trachomatis, 118
Campylobacter spp., 1385
combinations
oxacillin, 2037
Staphylococcus spp., 2037
comparative activity
ciprofloxacin, difloxacin, doxycycline, erythromycin, lomefloxacin, nalidixic acid, norfloxacin, and trimethoprim-sulfamethoxazole, 1385
ciprofloxacin, difloxacin, doxycycline, and norfloxacin, 118
M. tuberculosis, 591
Salmonella spp., 1385
Shigella spp., 1385
Vibrio spp., 1385
Yersinia spp., 1385
Terbinafine
W. dermatitidis, 1639
Testosterone
ciprofloxacin, 1875
tet
aminoglycoside uptake, 1549
gentamicin killing of *E. coli*, 230
Tet M
H. ducreyi, 1611
tetM
nucleic acid assay, 1813
Tetracycline
A. viridans resistance, 529
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
B. catarrhalis
resistance, 1631
B. melitensis, 1409
B. parapertussis, 968
bacterial vaginosis, 970
C. pneumoniae, 1634
C. pylori, 108
cholera, 1447
comparative activity
furazolidone, 1447
G. lamblia, 2144
H. ducreyi
resistance, 1611
M. leprae, 657
N. gonorrhoeae, 164
N. meningitidis, 1622
P. multocida
resistance, 670
resistance determinants
nomenclature, 1373
resistance gene expression
gentamicin killing of *E. coli*, 230
skin infections, 970
vaginosis, bacterial, 970
Tetramethylpiperidine
phenazine substitution
M. leprae, 2004
structure-activity relationships, 2004
Theophylline
metabolism
norfloxacin, effect of, 212
pharmacokinetics
lomefloxacin, effect of, 1006
Thiacycline
G. lamblia, 2144
Thiahexatroxane
T. gondii, 1748
7-Thia-8-oxoguanosine
antiviral activity, 1487
Thioridazine
T. b. brucei, 881
T. b. evansi, 881
Ticarcillin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
comparative activity
ceftazidime and ticarcillin-clavulanic acid, 693
clavulanic acid, piperacillin, piperacillin-tazobactam, tazobactam, ticarcillin-clavulanate, 1268
K. pneumoniae, 693
meningitis, 693
pharmacokinetics, 693
protective effect, role of sodium in, 928
gentamicin nephrotoxicity, 928
Ticarcillin-clavulanic acid
Acinetobacter spp., 1617
comparative activity
ceftazidime and ticarcillin, 693
clavulanic acid, piperacillin, piperacillin-tazobactam, tazobactam, and ticarcillin, 1268
K. pneumoniae, 693
meningitis, 693
pharmacokinetics, 693
Tigemonam
C. pylori, 1650
Tn*554*
characterization of insertion, 541
Tn*2610*
organization, 746
Tn*4031*
S. epidermidis, 1335
Tobramycin
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
combinations
daptomycin, 1280
comparative activity
aztreonam, 1137
E. coli
hyperoxia, 1526
gram-negative infections, 1137
nephrotoxicity, 1280
daptomycin, influence of, 1280
P. aeruginosa
exoenzymes, 41
hyperoxia, 1526
mucoid and nonmucoid PAO1, 1207
Staphylococcus resistance
restriction map, 1624
Topoisomerase II
assays
CP-67,015, 1697
ellipticine, 1697
nalidixic acid, 1697
norfloxacin, 1697
oxolinic acid, 1697
VP-16, 1697
quinolones, 1816
Topoisomerases
minireview
biochemical characteristics, 2027
physiological significance, 2027
Torulopsis glabrata
cilofungin, 1391
Tosufloxacin
comparative activity
ciprofloxacin, enoxacin, norfloxacin, and ofloxacin, 2140
Nocardia spp., 2140
Toxoplasma gondii
dihydrofolate reductase inhibitors, 1753
hexatroxanone, 1748
pentatroxane, 1748
piritrexim, 1753
pyrimethamine, 30, 1753
pyrimethamine-zidovudine, 30
sulfadiazine, 1753
sulfadiazine-piritrexim, 1753
sulfadiazine-pyrimethamine, 1753
sulfadiazine–trimetrexate-glycuronate, 1753
sulfamethoxazole, 1753
sulfisoxazole, 1753
sulfisoxazole-pyrimethamine, 1753
sulfonamides, 1753
thiahexatroxane, 1748
trimethoprim, 1753
trimethoprim-sulfamethoxazole, 1753
trimetrexate-glycuronate, 1753
1,2,4-trioxanes, 1748
Transmembrane diffusion
ciprofloxacin, 1379
enoxacin, 1379
Transposons
Tn*554*
S. aureus, 541
S. epidermidis, 541
Tn*2610* organization, 746
Treponema denticola
spiramycin, 2016
1,3,5-Triacetylbenzene tris(guanylhydrazone)trimethanesulfonate hydrate
T. b. brucei, 881
T. b. evansi, 881
Triazole analog
A. fumigatus, 895
C. albicans, 895
Candida spp., 895
E. floccosum, 895
efficacy-safety profile, 895
M. audouinii, 895
Trichophyton spp., 895
Trichloroacetic acid
aminoglycoside extraction, 448
Trichophyton mentagrophytes
piritetrate, 2118
Trichophyton spp.
imidazole analogs, 895
triazole analog, 895
Trichosporon cutaneum
antifungal-antineoplastic effects, 726
cancer patients, 726
Trimethoprim
E. coli
hyperoxia, 1526
P fimbriae, 684
M. leprae, 657
P. aeruginosa
hyperoxia, 1526

P. cepacia resistance, 1247
P. shigelloides, 1609
S. haemolyticus resistance, 460
T. gondii, 1753
Trimethoprim-sulfamethoxazole
Acinetobacter spp., 1617
B. avium, 771
B. bronchiseptica, 771
B. melitensis, 1409
C. jejuni, 248
C. pylori, 108
comparative activity
norfloxacin, 1101
ofloxacin, 1308
cystitis, 1308
E. coli, 1308
enteritis, 248
Enterococcus spp., 989
letter to the editor, 989
shigellosis, 1101
T. gondii, 1753
Trimetrexate-glycuronate
combinations
sulfadiazine, 1753
T. gondii, 1753
T. gondii, 1753
1,2,4-Trioxanes
T. gondii, 1748
Trospectomycin
comparative activity
spectinomycin, 569
N. gonorrhoeae, 569
susceptibility testing, 569
Trypanosoma brucei brucei
9-deazainosine, 881
DL-α-(difluoromethyl)ornithine hydrochloride monohydrate, 881
feeder layer-free screening system, 881
formicin B, 881
gossypol, 881
Ro 15-0216, 881
sinefungin, 881
taxol, 881
thioridazine, 881
1,3,5-triacetylbenzene tris(guanylhydrazone)trimethanesulfonate hydrate, 881
Trypanosoma brucei evansi
9-deazainosine, 881
DL-α-(difluoromethyl)ornithine hydrochloride monohydrate, 881
feeder layer-free screening system, 881
formicin B, 881
gossypol, 881
Ro 15-0216, 881
sinefungin, 881
taxol, 881
thioridazine, 881
1,3,5-triacetylbenzene tris(guanylhydrazone)trimethanesulfonate hydrate, 881
Tubercidin
host toxicity, prevention of
nitrobenzylthioinosine 5′-monophosphate, 824
schistosomiasis, 824

Unilamellar vesicles
liposomal amphotericin B, 345
Upper respiratory tract infections
zinc gluconate, 646
Ureaplasma urealyticum
BMY 40062, 906
pristinamycin, 2152
Urinary tract infections
cefaclor, 1212
cefuroxime axetil, 1212
ciprofloxacin resistance, 595
E. coli, 877
fluoroquinolones, 684
enoxacin
dosage comparison, 877
fluoroquinolones
E. coli P fimbriae, 684
minireview, 1655
iontophoresis, 442
letter to the editor, 595
norfloxacin, 1032
resistance, 595
Staphylococcus spp., 877

Vaccinia virus
S-adenosylhomocysteine, 828
3-deazaneplanocin A, 1291
DHCA, 1291
DHCDA, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-adenine, 828, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-3-deazaadenine, 828, 1291
(*S*)-HPMPA, 185
(*S*)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 185
neplanocin A, 1291
9-(2-phosphonylmethoxyethyl)adenine, 185
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, 185
PMEA, 185
PMEDAP, 185
Vaginosis, bacterial
clotrimazole, 970
fenticonazole, 970
metronidazole, 970
miconazole, 970
tetracycline, 970
Vancomycin
C. difficilie-associated disease, 1125
catheter-related infections, 1193
combinations
fleroxacin, 2037
Staphylococcus spp., 2037
comparative activity
ampicillin, ampicillin-sulbactam, daptomycin, and imipenem, 1019
ciprofloxacin, ciprofloxacin-rifampin, and rifampin, 1184
ciprofloxacin, clindamycin, gentamicin, penicillin, teicoplanin, and trimethoprim-sulfamethoxazole, 2019
daptomycin, 689, 1280
teicoplanin, 1125, 1193
derivatives
Enterococcus spp., 1477
Lactobacillus spp., 1477
Leuconostoc sp., 1477
Pediococcus spp., 1477
E. faecalis, 251, 1019
resistance, 198, 1121, 1588
susceptibility testing, 1588
E. faecium resistance, 1121
transferable, 10
endocarditis, 1019, 1184
endotoxemic rats
intrarenal distribution, 1575
pharmacokinetics, 1575
Enterococcus spp., 1477, 2019
Lactobacillus spp., 1477
Leuconostoc sp., 1477
minireview, 791
osteomyelitis, 689
ototoxicity, 791
Pediococcus spp., 1477
pharmacokinetics
endotoxemic rats, 1575
S. aureus, 689, 1184, 1280
S. haemolyticus resistance, 460
S. pneumoniae, 2019
Staphylococcus spp., 2019
surface colonizing, 813
Streptococcus spp., 580
Ventriculitis
ofloxacin penetration, 933
Vesicular stomatitis virus
3-deazaneplanocin A, 1291
DHCA, 1291
DHCDA, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-adenine, 1291
9-(*trans*-2′,*trans*-3′-dihydroxycyclopent-4′-enyl)-3-deazaadenine, 1291
neplanocin A, 1291
polymerase reaction
ribavirin, phosphorylated, 1668
ribavirin, phosphorylated
inhibition kinetics, 1668
7-thia-8-oxoguanosine, 1487
Vibrio spp.
lomefloxacin, 1385
temafloxacin, 1385
Vitamins with zinc
ciprofloxacin absorption, 1841
VP-16
topoisomerase II assays, 1697

Wangiella dermatitidis
amorolfine, 1639
amphotericin B, 1639
fluconazole, 1639
flucytosine, 1639
itraconazole, 1639
ketoconazole, 1639
melanin
antifungal susceptibility, 1639
terbinafine, 1639
WIN 54954
coxsackievirus, 2069
echovirus, 2069
enterovirus, 2069
rhinovirus, 2069
WIN 57273
comparative activity
ciprofloxacin and erythromycin, 2132
L. pneumophila, 2132

Xanthomonas maltophilia
AM-1091, 1036
ME1228, 1260
QA-241, 1144
SM-7338, 215, 562
Xanthomonas spp.
AT-4140, 1167

Yeasts
cilofungin, 731
flusilazole, 1228
SCH39304, 1095
Yersinia spp.
dactimicin, 1998
lomefloxacin, 1385
temafloxacin, 1385

Zidovudine
bioequivalence of syrup, solution, and capsule, 1801
combinations
castanospermine, 53
cytomegalovirus, 663
foscarnet, 663
human immunodeficiency virus type 1, 53, 663
human immunodeficiency virus type 2, 53
phosphonoformate, 663
pyrimethamine, 30
T. gondii, 30
comparative activity
ampicillin and trimethoprim, 479
E. coli, 479
fluorescence polarization immunoassay, 1275
human immunodeficiency virus, 1801
S. dublin, 479
Zinc gluconate
rhinovirus, 646
upper respiratory tract infections, 646